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ABSTRACT 
The tuberculosis (TB) epidemic remains a major threat to public health globally, and is 
exacerbated by the escalating number of multi-drug resistant cases. These factors have 
highlighted the urgent need for new effective therapies or different approaches to augment 
the efficacy of current anti-TB drugs. Synergistic drug combinations present a feasible 
strategy towards expanding TB treatment options. Despite reported successes with 
combination screening, as well as the current reliance on combination therapy for TB, this 
approach remains largely underexplored. Evidence suggests that utilizing synergistic 
combinations might enable existing clinically-approved drugs to be readily re-purposed for 
TB treatment, including against multi-(MDR) and extensively- (XDR) drug resistant strains 
for current therapies are often ineffective. 
This thesis focused on the development and application of improved methods to 
identify and advance novel drug combinations for TB therapy. There were two key aspects to 
this work: firstly, exploring mechanisms of synergy between fusidic acid (FSA), a natural 
product antibiotic, and current anti-TB agents and, secondly, characterizing antibiotic action 
by delineating bacteriostatic and bactericidal compounds.  
In the search for synergy, a drug repurposing/repositioning approach was adopted, 
chapters 2 and 3, in which FSA and its semi-synthetic derivatives were selected for 
combination studies with a drug panel consisting of known anti-TB drugs as well as 
translational inhibitors. Checkerboard assays and subsequent analyses of time-kill kinetics 
revealed seven drugs that synergized with FSA in inhibiting the growth of Mycobacterium 
tuberculosis. These included the rifamycin, rifampicin (RIF), and the macrolides, 
erythromycin (ERY), clarithromycin (CLR), and roxythromycin (ROX). Other agents which 
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synergized with FSA included the oxazolidinone, linezolid (LZD), the aminoglycoside, 
streptomycin (STR), and spectinomycin (SPC), an aminocyclitol. Among these, FSA 
exhibited strongest synergies with SPC and ERY, both returning a fractional inhibitory 
concentration index (FICI) value of 0.25. Notably, synergy with FSA was achieved in vitro at 
concentrations lower than the reported peak plasma concentrations achievable for all the 
drugs, with the exception of ERY. Moreover, those compounds synergizing with FSA also 
exhibited less lipophilicity, i.e low clogP values, suggesting the potential to penetrate the 
caseum, a characteristic currently prioritized in many TB drug discovery programmes.  
In order to inform judicious selection of FSA synergizing partners for further 
advancement, the activity of these compounds against drug-resistant mutants was also 
examined. No cross resistance was observed against a defined FSA-resistant (FSA-R) mutant 
and, furthermore, FSA-R mutant displayed increased susceptibility to STR and SPC 
compared to the WT strain. In chapter 3, combinations that exhibited varied degrees of 
potency against the WT strain  were also tested against the resistant mutants. These studies 
revealed the potential for synergistic combinations to restore activity against strains resistant 
to either one of the two partner drugs. For example, combining FSA (or its analogues) with 
SPC against wild-type M. tuberculosis H37Rv and a derivative FSA-resistant (FSA-R) or 
SPC resistant (SPC-R) mutant showed that potent interactions such as FSA plus SPC (FICI ~ 
0.15) retained synergistic inhibition against either resistant mutant. To leverage this finding, 
SPC was utilized in a three-drug interaction study that also included rifampicin (RIF) and 
isoniazid (INH). The combination of RIF-INH plus SPC used at sub-MIC’s exhibited synergy 
against the wild-type and RIF-resistant, rpoB mutant. This inhibitory effect supported the 
potential for SPC to overcome a pre-existing genetic resistance against one of the drugs in a 
combination therapy. 
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 Assigning bactericidal or bacteriostatic modes of action to experimental compounds 
has become an important consideration in early drug discovery programmes.  The second 
major component of this thesis aimed to develop a rapid and robust method for assessment of 
bactericidal/bacteriostatic compounds by integrating different strategies, including flow 
cytometry (FCM), fluorescent microscopy, and the spot assay technique. The results 
established that assigning mode of antibiotic action could be rapidly accomplished. Using 
FCM analyses of M. smegmatis, chapter 4, results were available within 1 h of exposure to 
the applied drug. Moreover, the use of FCM enabled a tentative inference of the drug’s target: 
cell wall synthesis inhibition versus the inhibition of other metabolic processes within the 
cell. Both FSA and SPC exhibited a late inhibition, 72 h post-exposure, suggesting an 
intracellular metabolic impairment. Morphological phenotyping by optical microscopy 
revealed heterogeneous mycobacterial populations composed of aggregated cells, triplets, 
doublets and singlets that differentially distributed across the two sub-populations of the 
exponential culture. The transition of M. smegmatis cell population from log phase to 
stationary phase was also accompanied with a cell size reduction. This may possibly be 
explained by the rearrangement in peptidoglycan in cell wall of the stationary phase bacteria 
leading to size reduction. 
In conclusion, this thesis describes experimental and analytical approaches designed 
to enable the  evaluation of synergistic drug interactions as a key component to the discovery 
and development of novel combination therapies and, moreover, suggests that application of 
high-throughput population biology techniques such as FCM enable rapid early triage of 
priority experimental compounds and combination therapies. 
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Chapter 1          
Introduction 
1.1. Background 
Mycobacterium tuberculosis is responsible for significant morbidity and mortality as well as 
imposing a massive public health and economic burden (Zumla et al., 2014). In 2015, there 
were an estimated 1.4 million deaths from tuberculosis (TB) and a further 0.4 million deaths 
arising from TB disease among people infected with HIV (WHO, ). Moreover, it is estimated 
that there are approximately two billion latent M. tuberculosis infections worldwide, which 
represents a massive reservoir of potential future disease (Zumla et al., 2015). Incident cases 
of TB were estimated at 10.4 million in 2015, equivalent to 142 cases per 100,000 
population, with 61% in Asia, and 26% in the African region (World Health Organization, 
2015). The Mediterranean accounted for 7% of the world’s cases, while Europe and the 
America’s each had 3% new cases (WHO, 2016 ). In addition, India, Indonesia, China, 
Nigeria, Pakistan and South Africa contributed to an estimated 60% of the global TB 
incidence in 2015 (WHO, 2016 ). Figure 1-1, shows the geographic distribution of TB 
incidence globally. 
 The existing TB prevalence can be ascribed to various features, notably, cases of 
increased drug resistance, co-infection with HIV, resettlement and migration of people, and 
active transmission in crowded environments such as prisons, refugee camps and hospitals 
(Ducati et al., 2006). The absence of a completely effective TB vaccine as well as the slow 
development of new antimycobacterial drugs have also exacerbated the re-emerging TB crisis 
(WHO, 2012).  
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      Figure 1-1 Estimated new TB cases, 2015 (WHO, 2016 ). 
Worse still, an estimated 1.1 million (13%) of TB cases in 2013 were HIV-positive 
individuals. Among these, the African region bore the greatest burden with four out of every 
five HIV-positive TB cases and TB deaths reported (World Health Organization, 2014). 
 
1.2.    Mycobacteria 
The genus Mycobacterium consists of mostly non-motile, Gram-positive bacilli whose 
genomes are characterized by high G+C percentage (62 – 72 %). They are rod-shaped, 
aerobic bacteria whose cell walls uniquely contain mycolic acids as a major component. The 
wax-like cell wall for this genus is associated with unique characteristics of acid-fastness and 
intense hydrophobicity. In addition, they are less prone to desiccation, changes in 
acidity/alkalinity and are generally tolerant of antibiotics (Barry et al., 1998; Daffe & Draper, 
1998).  
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1.2.1. M. tuberculosis pathogenesis  
In 1882, Robert Koch identified M. tuberculosis, a member of the Mycobacteriaceae family, 
as the causative agent of TB (Kaufmann & Schaible, 2005). M. tuberculosis is a clinically 
important bacilli that belong to the M. tuberculosis complex (or MTBC), a group comprised 
of closely related mycobacterial pathogens which includes M. africanum, M. bovis, M. 
canettii and M. microti (Russell, 2001). M. tuberculosis is a slow grower with a generation 
time of approximately 20 h under standard aerobic conditions in vitro (Dartois, 2014). It 
requires two to three weeks of incubation for any visible growth to be detected on solid media 
at 37°C (Murray et al., 2007). Moreover, it is known to replicate and survive within the host 
macrophage cells, which distinguishes M. tuberculosis from many other pathogens. M. 
tuberculosis is transmitted by aerosol into the lungs. It largely inhabits the professional 
phagocytic cells; macrophages, neutrophils, monocytes and dendritic cells (Kang et al., 2011; 
Wallgen, 1948). After phagocytosis, neutrophils, lymphocytes and macrophages move 
towards the lesion, leading to formation of a granuloma, a wall of macrophages and immune 
cells intended to contain the infection. In other infectious diseases, the recruitment of 
phagocytic cells restricts and even eliminates invading pathogens, whereas in M. 
tuberculosis, the granuloma structure allows it to continue growing and overcome the 
immune response during the early stages of infection (Davis & Ramakrishnan, 2009). Inside 
the granuloma, the bacilli can be metabolically quiescent leading to latent TB infection. In 
less than 10% of latent TB infections, there is reactivation of infection, exacerbated by many 
factors which result in an immunocompromised state. Such factors include HIV infection, 
immunosuppression, or treatment with anti-TNF-α  (Kumar et al., 2011). 
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1.3. Antibacterial agents 
Infectious diseases, for example TB, which are caused by bacteria can be treated or managed 
by using antibiotics. These agents are natural, semi-synthetic or synthetic compounds that 
kill, or inhibit the growth of, bacteria. The bacteria can be susceptible to antibiotics resulting 
in growth inhibition or death. Yet, in some cases, the bacteria may remain unaffected, or may 
even acquire resistance (Stefanovic-Racic et al., 2012). 
 
 
Penicillin (PEN) 
Vancomycin (VAN) 
Bacitracin 
(BAC) 
Figure 1-2 Examples of cell wall biosynthesis inhibitors 
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Antibiotics can be classified primarily into five groups based on the metabolic 
pathway or macromolecular structure they affect. These include: (i) cell wall biosynthesis 
inhibitors, for example penicillin (PEN), vancomycin (VAN), bacitracin (BAC), (Figure 1-
2). PEN, a beta lactam antibiotic, blocks the final step of peptidoglycan synthesis by 
inhibiting the action of transpeptidation enzymes. BAC and VAN, on the other hand, target 
the early stages of   peptidoglycan synthesis (Baggot, 1998); (ii) protein biosynthesis 
inhibitors, which target certain subunits of microbial ribosomes, for example macrolides such 
as erythromycin (ERY) and clindamycin (CLI), the aminoglycosides, amikacin (AMK) and 
kanamycin (KAN), as well as tetracycline (TET) and chloramphenicol (CHL), (Figure 1-3); 
Erythromycin (ERY) 
Clindamycin (CLI) Tetracycline (TET) 
Kanamycin (KAN) 
Chloramphenicol (CHL) 
Amikacin (AMK) 
Figure 1-3 Examples of protein biosynthesis inhibitors 
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(iii) DNA replication/ repair inhibitors, including the fluoroquinolones ciprofloxacin (CIP), 
moxifloxacin (MXF) and ofloxacin (OFX) (Figure 1-4); (iv) RNA synthesis inhibitors, for 
example rifampicin (RIF), a rifamycin (Ali et al., 1993) (Figure 1-5), and (v) inhibitors of 
folic acid synthesis, for example pyrimethamine (PMT),  trimethoprim (TMP) and the 
sulfonamide, sulfamethoxazole (SMX) (Baggot, 1998)  (Figure 1-6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
             
Ciprofloxacin (CIP)      Moxifloxacin (MXF) 
Ofloxacin (OFX) 
Gatifloxacin (GAT) 
Rifampicin (RIF) 
Figure 1-4 Examples of DNA replication/repair inhibitors 
Figure 1-5  Example of RNA synthesis 
inhibitor 
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1.3.1. Translational inhibitors   
The translational apparatus of bacteria has been shown to be a major target of antibiotics. In 
this case, the antibiotics act predominantly on the three functional centres of the ribosome: 
the messenger RNA (mRNA)-transfer RNA (tRNA) decoding region on the 30S subunit, the 
peptidyl transferase centre of the 50S subunit and, lastly, the ribosomal exit tunnel, which 
allows the passage of the nascent polypeptide chain. Protein translation can be categorized as: 
the initiation, elongation and termination or recycling (Figure 1-7). With the exception of 
aminoglycosides, most antibiotics that act on the ribosome are bacteriostatic (Kohanski et al., 
2007).
1.3.1.1. Antimicrobials acting on the 30S part of the ribosome 
Aminoglycosides such as streptomycin (STR) and gentamicin (GEN) (Figure 1-8) trap the 
30S initiation complex (30S-mRNA-tRNA) by binding at the 16S ribosomal RNA, thereby 
preventing any further initiation. They also induce misreading of mRNA, which results in 
slowing down of protein synthesis. Binding of aminoglycosides to the 16S rRNA enhances  
the binding of tRNA to the A site irrespective of the anticodon specificity. 
Sulfamethoxazole (SXT) Pyrimethamine (PMT) Trimethoprim (TMP) 
Figure 1-6 Examples of folic acid biosynthesis inhibitors 
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Figure 1-7 Antibiotic targets during protein synthesis. Schematic representation of antibiotics acting at different stages in the translation process. The three 
main tRNA binding sites on the ribosome; A-, P-, and E-sites. (Adopted and modified from Wilson,  2009) 
11 
 
Tetracyclines are bacteriostatic agents that include TET, minocycline (MIN) and doxycycline 
(DOX) (Figure 1-9). They bind reversibly to the 30S subunit, and thereby prevent the 
accommodation of aminoacyl-tRNA to the acceptor site of the 70S ribosome (Wilson, 2009). 
 
 
              
  
   
 
 
 
 
                                     
 
 
 
 
 
Spectinomycin (SPC) 
Streptomycin (STR) 
Gentamicin (GEN) 
Minocycline (MIN) 
Doxycycline (DOX) 
Figure 1-8 Examples of aminoglycosides 
Figure 1-9 Examples of tetracyclines 
Figure 1-10 Example of an 
aminocyclitol 
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The aminocyclitol class is exemplified by SPC (Figure 1-10), and is structurally similar to 
aminoglycosides; these antibiotics interfere with mRNA interactions with the 30S ribosome 
(Hoeksema & Knight, 1975; Lyutzkanova, Distler & Altenbuchner, 1997). 
                                                                 
1.3.1.2. Antimicrobials that target  elongation factors in protein synthesis 
Fusidic acid (FSA) (Figure 1-11) is a focus of this study. This drug acts on  elongation factor 
G (EF-G). FSA interferes with the release of EF-G from the EF-G/GDP complex (Turnidge 
& Collignon, 1999).  
 
 
 
                 
 
 
                             
1.4. TB treatment regimens 
The difficulty encountered in eradicating M. tuberculosis with the currently available drugs, 
as well as the long treatment duration, are factors contributing to the increasing occurrence of 
MDR strains (Reddy et al., 2010).
 
 Moreover, about 11-13% of TB patients worldwide are co-
infected with HIV, which complicates the treatment owing to drug-drug interactions or 
related toxic side-effects (Koul et al., 2011). 
 
Furthermore, TB-HIV co-infected patients are at 
risk of developing immune reconstitution inflammatory syndrome (Gengiah et al., 2011). The 
current first–line anti-TB chemotherapy consists of a four-drug combination: RIF, isoniazid 
Figure 1-11 Fusidic acid (FSA) 
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(INH), pyrazinamide (PZA) and ethambutol (EMB) (Figure 1-12) (Kaneko, Cooper & 
Mdluli, 2011)  
RIF has been the backbone of TB chemotherapy since its discovery in the 1960s. It 
targets the rpoB-encoded β subunit of RNA polymerase, an enzyme that catalyses 
transcription (Zumla, Nahid & Cole, 2013; Cohen, 2013)
  
INH, introduced in 1953, has been 
very effective since its development (Miesel et al., 1998; Almeida et al., 2007). It inhibits the 
synthesis of mycolic acids that form long chain fatty acids, which contribute to the structural 
composition of the cell wall (Miesel et al., 1998; Winder & Collins, 1970). PZA, which was 
developed in the mid-1980s, has structural similarities to INH (Shi et al., 2011; Scorpio & 
Zhang, 1996).  Until recently, it was believed that PZA - through its bioactive derivative, 
pyrazinoic acid (POA) - exerted its action on M. tuberculosis by disrupting membrane 
energetics resulting in inhibition of membrane transport function (Zhang et al., 2003). 
 
 
However, recent findings suggest a different mode of action involving PZA/POA. 
Gopal et al. demonstrated that POA depletes coenzyme A (CoA), an essential acyl carrier, in 
wild type bacteria. In addition, they found resistance conferring mutations in two pathways: 
missense mutations in aspartate decarboxylase, panD, involved in synthesis of CoA and 
RIF 
Isoniazid (INH) Pyrazinamide (PZA) 
 
 
Ethambutol (EMB) 
Figure 1-12 Current anti-TB first-line drugs. 
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frameshift mutations in the in vitro non-essential polyketide synthase genes, mas and ppsA-E, 
involved in the synthesis of the virulence factor phthiocerol dimycocerosate (PDIM) (Gopal 
et al., 2016). In another study, Shi et al. identified the ribosomal protein S1 (RpsA), encoded 
by the rpsA gene as the possible target of POA. RpsA is associated with protein translation 
process and maintenance of fidelity in protein synthesis; or trans-translation (Shi et al., 2011). 
Evidence by Yang et al. also suggested that the binding of POA to RpsA led to the inhibition 
of trans-translation. In this study, crystal structures of the C-terminal domain of RpsA in M. 
tuberculosis were reported in complex with POA, as well as the corresponding domains of 
two RpsA variants associated with PZA resistance (Yang et al., 2015). Lastly, EMB, 
discovered in 1961 kills actively multiplying bacilli by inhibiting arabinosyl transferases 
involved in cell-wall biosynthesis (Takayama & Kilburn, 1989; Shi et al., 2011). 
 
 
Subsequent to the discovery and FDA approval of RIF, no new TB drug was 
developed for almost 50 years. Recently, however, bedaquiline (BDQ), also known as TMC 
207 (Figure 1-13), received FDA approval for the treatment of MDR-TB cases (Cohen, 
2013). It is highly effective on non-replicating bacilli of drug-susceptible, MDR, and XDR 
M. tuberculosis strains and acts by inhibiting ATP synthase, blocking mycobacterial ATP 
generation (Andries et al., 2005; Rivers & Mancera, 2008).
 
However, it has been shown to 
cause serious side effects such as irregular heart rhythms that can result in cardiac arrest. 
Results of clinical trials have revealed a 4.5-fold higher mortality of groups treated with BDQ 
compared to the control (Cohen, 2013).
 
 Moreover, it is not yet clear whether this drug can be 
safely combined with the current HIV medications (Giffin & Robinson, 2009). These 
shortcomings, and the fact that fewer than 10% of drug candidates pass clinical trials 
successfully, reinforce the pressing need for new anti-TB drugs (Giffin & Robinson, 2009). 
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1.4.1. Resistance of M. tuberculosis to current anti-TB treatment 
The renewed search for new anti-TB drugs has been further necessitated by the emergence of 
MDR strains, which are defined as resistant to the frontline agents, INH and RIF.  
Extensively drug-resistant (XDR) TB strains are defined as MDR strains that have gained 
resistance to any fluoroquinolone and at least one of the three injectable second-line drugs 
(Figure 1-14) (Zignol et al., 2006; Basu & Galvani, 2008). 
 
 
By the end of 2015, representative data from continuous surveillance in 88 WHO 
member countries within the five territories indicated an average of 9.5% of MDR-TB cases 
as XDR-TB.(WHO, ) However, this representation could be an underestimation owing to the 
difficulty in the diagnosis of tuberculosis. As noted in a study by Dheda et al, the challenges 
include patients 
 
 
 
Figure 1-13 Bedaquiline, BDQ 
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with scant or no sputum, an extrapulmonary presentation or low sputum mycobacterial 
burden - same day sputum test negative. In some cases, sputum induction and organ or tissue 
biopsy might be needed, but are not always available in the resource poor settings. 
Accordingly, these challenges in diagnosis as well as other health-system associated factors 
add to the diagnostic gap of an estimated 3 million undiagnosed tuberculosis cases globally 
(Dheda, Barry 3rd & Maartens, 2015). 
 Chromosomal mutations are primarily responsible for the drug resistance in TB. 
These mutations affect either the drug target itself, or bacterial enzymes that activate 
prodrugs, or efflux pumps (Sandgren et al., 2009). The emergence of clinical drug resistance 
in TB (Figure 1-15) is categorized as acquired resistance when drug resistant mutants are 
selected as a result of ineffective treatment or as primary resistance when a patient is infected 
with a resistant strain (Johnson et al., 2007). A number of mutations in isolates resistant to 
           KAN        AMK 
Capreomycin (CAP) 
Viomycin (VIO) 
Ethionamide (ETH) p-aminosalicylic acid (PAS) 
D-cycloserine (DCS) 
Figure 1-14 Examples of second-line anti-TB drugs. 
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specific drugs have been elucidated in M. tuberculosis (Ramaswamy & Musser, 1998). In the 
case of drugs like INH and RIF, considerable mutations have been established that confer 
resistance (estimated spontaneous mutation frequency of 3.5 x 10
-6
 for INH and 3.1 x 10
-8
 for 
RIF), and these mutations account for most resistance observed with the clinical isolates 
(Dooley & Simone, 1994). Due to the fact that the respective gene locations associated with 
resistance to different drugs are not joined together, the probability of a simultaneous 
spontaneous mutation is extremely low: 9 x 10
-14
 for both INH and RIF (Sandgren et al., 
2009).
 
Mutations that occur throughout the pncA gene have also been shown to correlate 
closely with phenotypic PZA resistance (Barco et al., 2006).
 
Besides, drugs such as STR and 
other second-line agents have far less resistant mutations within the drug-resistant population 
(Ramaswamy & Musser, 1998). 
 
                        
Figure 1-15 Acquired resistance versus Primary resistance in TB. (Adopted and modified 
from  Zhang et al., 2007). 
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1.4.2. New anti-TB drug development 
A number of clearly defined criteria are considered in developing new drug candidates for 
TB, of which a validated safety profile forms a critical aspect. Besides, the new drug should 
exhibit a superior potency in comparison with the existing drugs in order to shorten the 
duration of treatment; should potentially inhibit novel targets to successfully overcome MDR 
and XDR-TB; should allow for the concomitant administration  with ART as many TB 
patients are co-infected with HIV; and should not have antagonistic effects with existing anti-
TB drugs or those under development so that a regimen of three drugs or more can be 
administered (Global Alliance for TB Drug Development, 2001; Cole & Riccardi, 2011; Koul 
et al., 2011).
 
After about five decades of very limited activity in the field of anti-TB drug 
development, much more progress has been made in the very recent past. This has resulted in 
the emergence of a TB drug pipeline with promising drug candidates (Figure 1-16). 
However, due to the high attrition rate of drug candidates during clinical development and 
new cases of drug resistance, the discovery of new lead molecules is without a doubt needed 
 
(Pethe et al., 2013). In this drug pipeline, it can be seen that many drug candidates are in lead 
optimization, preclinical development, as well as phase 2 and phase 3 clinical studies. 
However, phase 1 needs urgent attention in order to ensure a constant delivery of molecules 
in case of failure of advanced drug candidates. Figure 1-17 shows the chemical structures of 
some of the current anti-TB drug candidates. 
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BDQ (Andries et al., 2005).  PBTZ-169 (Makarov et al., 2009), and imidazopyridine 
amide Q-203 (Pethe et al., 2013), were identified through phenotypic screening of 
compounds against M. tuberculosis. SQ109, a 1, 2-ethylenediamine {N0-(2-
adamantyl)-N-[(2E)-3, 7-dimethylocta-2, 6-dienyl] ethane-1, 2-diamine} was 
designed around the active 1, 2-ethylenediamine pharmacophore of EMB. It targets 
MmpL3, a member of the MmpL (Mycobacterial membrane protein, Large) family, in 
M. tuberculosis (Tahlan et al., 2012). 
 
MmpL3 is required for the transportation of 
mycolic acids, in the form of trehalose monomycolates (TMM), into the M. 
tuberculosis cell wall (Tahlan et al., 2012). It also plays an important role in haem 
uptake by helping in the acquisition of iron for mycobacterial survival. Therefore, 
MmpL3 is considered an attractive target for anti-TB drug discovery since it is the 
Figure 1-16 Current global drug pipeline (modified by www.newtbdrugs.org) updated October, 
2016. 
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only protein in this family, essential for the survival of M. tuberculosis (Nguta et al., 
2015). In addition, recent results by Li et al showed the synergy potential of MmpL3 
inhibitors with two different chemotypes, indolcarboxamides and adamantyl ureas. 
These inhibitors demonstrated synergistic interactions with RIF, BDQ, clofazimine 
and ß-lactams (Li et al., 2017). SQ109 possesses polypharmacological properties; 
exhibiting activity in bacteria and fungi that do not have mycolic acids (Biava et al., 
2007). Delamanid (OPC-67683) and pretomanid (PA-824) are two new 
imidazooxazole-based prodrugs. They are activated intracellularly by Rv3547, a 
deazaflavin-dependent nitroreductase (Ddn) present in M. tuberculosis. The des-
nitroimidazole metabolite was identified as the active form of PA-824. This molecule 
releases reactive nitrogen species, such as nitric oxide, leading to respiratory 
poisoning (Singh et al., 2008). Delamanid, on the other hand, inhibits mycolic acid 
biosynthesis and has shown potent in vitro and in vivo activity against MDR strains 
(Gler et al., 2012). Rifapentine (RFP), a semi-synthetic cyclopentyl rifamycin 
derivative, acts by binding the ß subunit of the RNA polymerase in M. tuberculosis, a 
similar mechanism utilized by RIF (Munsiff, Kambili & Ahuja, 
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2006)
 
 
RFP is effective against both active and latent TB but shows cross-resistance with RIF (Pethe 
et al., 2013).  Moreover, RFP is not recommended for use in patients infected with HIV 
owing to the high risk of developing RIF resistance. Q-203, an optimized imidazopyridine 
amide (IPA), blocks M. tuberculosis growth by interfering with cytochrome oxidase bc1 
complex, a component of respiratory electron chain, required for maintaining a proton 
gradient and ATP synthesis (Zumla, Nahid & Cole, 2013;
  
Pethe et al., 2013).
 
 Despite the 
fact that both BDQ and Q-203 act on the respiratory chain of M. tuberculosis, the latter is 
more potent in ATP synthesis inhibition (Pethe et al., 2013) PBTZ-169, which is at the pre-
clinical development stage of the drug pipeline, inhibits the enzyme decaprenylphosphoryl-β-
PBTZ-169 
Q-203 
SQ-109 
Delamanid 
Pretomanid 
Rifapentine (RFP) 
Figure 1-17 Anti-TB drug candidates 
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D-ribose 2´ epimerase (DprE1) (Merle et al., 2014), an oxidase involved in the biosynthesis 
of decaprenylphosphoryl-D-arabinose (DPA), which is a key precursor in the biosynthesis of 
the cell wall arabinans (Merle et al., 2014; Ribeiro et al., 2011). The mechanism of action of 
PBTZ-169 is similar to other benzothiazones, as it involves activation of an aromatic nitro 
group. The nitro group is required for activity conjointly with a meta electron-withdrawing 
group such as a trifluoromethyl or another nitro dinitrobenzenes (Figure 1-18) (Hoagland, 
Zhao & E Lee, 2016).  The nitroaromatic group is selectively reduced to a corresponding 
reactive nitrosoarene.  The nitroso group further reacts with the  cysteine residue in the 
DprE1 enzyme to form a covalent bond between the two species and consequently 
inactivating the enzyme (Trefzer et al., 2010).   Inhibition of this enzyme leads to cell lysis 
and bacterial death (Merle et al., 2014). Notably, the reductive metabolism in humans is not 
capable of activating PBTZ-169 or its related chemical series, thus providing an appropriate 
safety margin as confirmed by a negative Ames test for DNA mutagenesis (Hoagland, Zhao 
& E Lee, 2016). 
 
Covalent adduct 
reduction 
PBTZ-169 Nitroaserene intermediate 
Figure 1-18 PBTZ -169 with the covalent inhibition mechanism of DprE1  (Hoagland, Zhao &  
Lee, 2016).  
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1.4.3. Repurposed drugs for TB treatment 
The development of new drugs is onerous, costly and often time-consuming (Scannell et al., 
2012). Moreover, besides efficacy, most of the compounds fail to progress to approval due to 
toxicity-related concerns (DiMasi et al., 2010). In order to overcome these bottlenecks, drug 
repurposing and/or repositioning have become attractive strategies  (Strittmatter, 2014). Drug 
repurposing refers to the process of finding new use for existing, approved drugs 
(Strittmatter, 2014). On the other hand, drug repositioning involves carrying out structure 
modifications of an existing drug, abandoned or shelved compounds and candidates under 
development, for a new indication (Nzila, Ma & Chibale, 2011; Naylor, 2015). 
There are several strategies that have been employed to identify drugs with the 
potential for new uses. The unintended second benefit may manifest as a result of clinical 
observation in one group, as observed with the treatment using clofazimine (CFZ; Figure 1-
20) (O'Donnell, Padayatchi & Metcalfe, 2016). CFZ, is a highly lipophilic drug that readily 
gets into the fatty tissues with and is taken up by human mononuclear phagocytes, the cells 
affected with M. tuberculosis.  In addition, a compound may target a condition, different from 
the one originally intended. For example, the compound AZD0530 targets tyrosine-protein 
kinase Fyn, encoded by the fyn gene in humans. AZD05030 may therefore be broadly utilized 
to target tyrosine-protein kinase Fyn, an enzyme that is key to the mechanism of Alzheimer’s 
disease and in the proliferation of tumour cells (Nygaard, van Dyck & Strittmatter, 2014).  A 
compound may also act on a novel target associated with various disease states (Strittmatter, 
2014). The following drugs have been repurposed: 
Fluoroquinolones: These drugs have been used widely since they possess a broad-spectrum 
antibiotic action and are quite potent (Zumla, Nahid & Cole, 2013). They act by inhibiting the 
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enzymes topoisomerase II and IV, thereby interfering with DNA replication (Drlica & Zhao, 
1997). Examples include MXF and GAT (Figure 1-4), which exhibit bactericidal properties 
against M. tuberculosis both in vitro and in vivo (Gillespie & Billington, 1999; Miyazaki et 
al., 1999). They are already used as second-line treatment for TB (Moadebi et al., 2007). 
Oxazolidinones: These are exemplified by linezolid (LZD), sutezolid and AZD5847, (Figure 
1-19). LZD has originally been used for indications caused by Gram-positive bacteria such as 
skin infections and the hospital-acquired pneumonia (HAP) (Leach et al., 2011). In addition, 
LZD was reported to exhibit anti-TB properties and favourable clinical efficacy (Fortun et al., 
2005; Yang et al., 2012). It inhibits protein synthesis  by binding to the P site of the 50S 
ribosomal subunit (Figure 1-7). Mutations at the 23S rRNA made possible the identification 
of a peptidyl transfer centre as the exact site of action (Kloss et al., 1999). Besides the in vitro 
and in vivo activity of LZD against M. tuberculosis (Ashtekar et al., 1991),  other studies 
have shown that it exhibits a synergistic interaction with RIF in drug-susceptible M. 
tuberculosis strains, suggesting the potential to control selection of resistant mutants 
(Zurenko et al., 1996; Cynamon et al., 1999). Supported by these studies, LZD was used on a 
controlled number of TB patients to evaluate its efficacy and tolerability after long-term use. 
Results showed that, while LZD was effective in treating MDR-TB patients, its prolonged 
use was associated with toxicity causing anaemia and peripheral neuropathy (Ntziora & 
Falagas, 2007). However, the proven efficacy of LZD in treating MDR-TB cases has 
occasioned other investigations with sutezolid and AZD5847, belonging to a class of second-
generation oxazolidinones with greater selectivity on M. tuberculosis and fewer side effects 
(Hoagland, Zhao & E Lee, 2016). 
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Riminophenazines: These are exemplified by CFZ. (Figure 1-20), a lipophilic drug used for 
the treatment of leprosy. This drug may play a major role in the treatment of MDR-TB (Barry 
et al., 1957; Dey et al., 2013). Based on limited studies, and due to a shortage of therapeutic 
alternatives when dealing with more severe cases of drug resistant TB, CFZ is now included 
in group 5 of WHO’s third-line drugs for MDR-TB (Cholo et al., 2012).  The exact mode of 
action of CFZ is not completely known but recent studies have suggested the outer membrane 
as a possible target (Cholo et al., 2012). 
 
                                                              
 
In a different study, it was shown that NADH dehydrogenase in M. tuberculosis reduces CFZ 
and, after spontaneous reoxidation, subsequently releases levels of reactive oxygen species 
Figure 1-20 Clofazimine (CFZ) 
Figure 1-19 Oxazolidinone class of compounds 
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(ROS) that are bactericidal (Yano et al., 2011). Hartkoon et al. reported that gene mutations 
in Rv0678, a transcriptional regulator,  was associated with the up regulation of the 
multisubstrate efflux pump; MmpL5. These not only caused resistance to CFZ but also BDQ 
(Hartkoorn, Uplekar & Cole, 2014). 
β lactams: Are a populous class of antibiotics (Figure 1-21). Besides, they also form the 
mainstay of most of the antibacterial drug treatment regimens. Yet, the efficacy of β-lactams 
against M. tuberculosis has traditionally been considered very  limited (Hoagland, Zhao & E 
Lee, 2016). Members of this class of antibiotics act by inhibiting membrane-bound 
transpeptidases, which play an important role in crosslinking the peptidoglycan layer of the 
cell wall (Hugonnet & Blanchard, 2007). Apart from its thick impermeable cell wall, M. 
tuberculosis has a highly active ß-lactamase enzyme, BlaC, which makes it inherently 
resistant to ß-lactam antibiotics (Hugonnet & Blanchard, 2007). Carbapenems, however, have 
so far been successful against M. tuberculosis since they interact with the penicilin binding 
proteins that have a high-molecular-weight. In addition, they inactivate the  
 
 
 
 
 
 
 
Clavunate 
Tebipenem 
Clavulanic acid Faropenem 
Figure 1-21 ß-lactams 
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L,D-transpeptidases that form the 3 3 crosslinks existing in the unique M. tuberculosis cell 
wall (Dubee et al., 2012). Carbapenems are also less favourable substrates for BlaC, which is 
expressed at high levels thereby inactivating most other ß-lactams. The combination of ß-
lactamase inhibitor,clavulanate,  with carbapenems displayed activity against M. tuberculosis 
in vitro and in a murine model (England et al., 2012). Moreover, a case study showed that 
this drug combination was effective in treating six immunocompromised patients with XDR-
TB infection (Payen et al., 2012). The ß-lactam tebipenem, originally developed to treat 
otolaryngoligical and respiratory infections in pediatrics, has been identified to be the most 
potent anti-TB oral carbapenem when combined with clavulanic acid (Horita et al., 2014). 
Structural modification of the carbapenem resulted in faropenem, a penem with a slightly less 
strained ring system and, consequently, improved chemical stability (Milazzo et al., 2003). Its 
prodrug ester, faropenem medoxomil, allows for oral administration, a desirable property in 
MDR-TB treatment (Milazzo et al., 2003
;
 Schurek et al., 2007).   
  
1.4.4. Fusidic acid/and or  its derivatives as  potential anti-TB agent(s). 
FSA, a hydrophobic, narrow spectrum antibiotic was first isolated  from the fungus Fusidium 
coccineum by Godtfredsen et al. in 1962 and developed for clinical use by Leo laboratories in 
Ballerup, Denmark (Godtfredsen & Vangedal, 1962). This drug, possess antibacterial activity 
against Gram-positive bacteria (Collignon & Turnidge, 1999; Hoffner et al., 1990), and
 
is 
licensed for use as its sodium salt sodium fusidate. It is approved for use under prescription in 
South Korea, Japan, UK, Canada, Europe, Australia, New Zealand, Thailand, India and 
Taiwan. FSA inhibits bacterial replication and does not kill the bacteria, and is therefore 
termed bacteriostatic. However, at high concentrations between 2 to 32-fold higher than the 
MIC, it shows bactericidal tendency (Verbist, 1990). 
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It has a steroidal-like structure − bearing a well defined tetracycline ring, even though 
they differ from each other in the sterical conformation around the hexamer ring – 6  
                                       
 
membered carbon ring. Unlike tetracyclic triterpenes and sterols, fusidic acid has an unusual 
stereochemistry of the cyclopentanoperhydrophenanthrene ring system. Rings A, B and C are 
arranged in trans-syn-trans manner in contrast to usual trans-anti-trans arrangement in 
tetracyclic triterpenes and sterols. This unusual trans-syn-trans arrangement forces ring B to 
have a boat conformation (Figure1-22) (Godtfredsen et al., 1966). Thus, FSA and other 
fusidane antibiotics, assume a chair-boat-chair conformation which is essential for their 
function (Duvold et al., 2001). It is a weak acid (pKa of 5.7) and is mostly ionized in plasma 
and tissue at the physiological pH of 7.4  
 FSA is mainly used against staphylococci, including strains resistant to other 
antibiotics (Collignon & Turnidge, 1999). It is primarily used in the treatment of skin and eye 
infections. Occasionally, it is used systemically to treat bone and joint infections and 
septicaemia (Atkins & Gottlieb, 1999; Darley & MacGowan, 2004). Moreover, FSA has 
exhibited efficacy against other pathogens such as Norcadia sp. (Black & McNellis, 1970), 
Actinomyces and Clostridia spp. (Von Daehne, Godtfredsen & Rasmussen, 1979).  The 
potential of FSA’s  therapeutic  utility is demonstrated by its excellent tissue distribution, 
absence of known allergy, low toxicity as well as the nonexistence of clinically relevant cross 
Figure 1-22 Trans-syn-trans arrangement of  
cyclopentanoperhydrophenanthrene ring system 
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resistance with any of the commonly used antibiotics (Christiansen, 1999; Turnidge & 
Collignon, 1999). It distributes well into all human body compartments except the 
cerebrospinal fluid (Taburet et al., 1990), has a half-life of approximately 10 h, and exhibits 
minimal host toxicity (Reeves, 1987). 
 
 While FSA is the only fusidane antibiotic in clinical use, a number of steroid-like 
antibiotics from natural products have been identified (Chain et al., 1943). Ramycin, an 
antibiotic isolated from Mucor ramannianus (Vanderhaeghe, Van Dijck & De Somer, 1965), 
and helvolic acid, isolated from Aspergillus fumigatus and Cephalosporium caerulens 
(Okuda et al., 1964) (Figure 1-24) are examples of naturally occurring fusidanes with 
identical chemical structures to FSA. The other steroid-like related antibiotic is cephalosporin 
P1 produced by Cephalosporium acremonium (Von Daehne, Godtfredsen & Rasmussen, 
1979)   
                                      
 
As already mentioned, FSA targets elongation factor G (EF-G) thereby inhibiting 
peptide elongation in the ribosome and the process of ribosome recycling (Figure 1-7). It 
stalls the ribosome in complex with EF-G and GDP (Turnidge & Collignon, 1999). Studies 
have shown that FSA has a low affinity for unbound EF-G but forms a strong complex when 
EF-G is bound to the ribosome (Okura, Kinoshita & Tanaka, 1971; Willie et al., 1975a). EF-
Ramycin 
Helvolic acid 
Figure 1-23 Examples of fusidanes 
   30 
 
 
G has a dual role in bacterial protein synthesis in that it (1) catalyses mRNA translocation 
during the peptide elongation cycle, and (2) in conjunction with the ribosome recycling 
factor, speeds the dissociation of  the ribosomal sub-units after a round of protein synthesis 
termination (Hirashima & Kaji, 1973) for the start of a new round of mRNA translation 
(Karimi et al., 1999). Thus, FSA inhibits both peptide elongation and ribosome recycling 
(Hoffner et al., 1996; Savelsbergh, Rodnina & Wintermeyer, 2009). 
M. tuberculosis is susceptible to FSA. A previous study reported a MIC against M. 
tuberculosis of 16 to 64 µg/ml (Collignon & Turnidge, 1999). In another study that utilized 
the in vitro agar proportion method, 64 strains of M. tuberculosis were tested and the activity 
of FSA was reported at 16 µg/ml. Moreover, a study that investigated 30 M. tuberculosis 
strains (11 of them resistant to first-line drugs), the activity of FSA was below 32 µg/ml for 
all except three strains in which it was 64 µg/ml (Cicek‐Saydam et al., 2001). Yet, another 
study involving FSA, was performed in vitro against 170 clinical isolates of M. tuberculosis 
using a proportion dilution method.  This study revealed that nineteen isolates were resistant 
to at least one first-line anti-tuberculosis drug. A total of 1.8% of the isolates was resistant to 
FSA. In addition, no cross-resistance was found between first-line drugs and FSA 
(Cicek‐Saydam et al., 2001) 
When compared to other antibiotic classes, not much has been studied on the 
mechanisms and genetics of resistance to FSA (Turnidge & Collignon, 1999). Turnidge and 
Collignon (Turnidge & Collignon, 1999) have, however, shown that the FSA resistant 
mutants could readily be selected from an initial high inoculum. in Staphylococcus aureus. 
Furthermore, the entire bacterial populations revealed a spontaneous single-step 
chromosomal mutations were  in fusA, the gene coding for EF-G, at a rate of 1 in 10
6
 - 10
8
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cell divisions. This occurs even for the isolates from individuals previously not exposed to 
FSA (Turnidge & Collignon, 1999). Chopra first showed that resistant mutants of 
Staphylococcus aureus selected on FSA-containing media had altered EF-G (Chopra, 1976). 
Moreover, altered EF-G has been shown in Gram-negative bacteria, which give MICs much 
greater than the wild type strains (Dahlfors & Kurland, 1990). In Salmonella typhimurium, 
altered EF-G has been reported to be caused by mutations in three specific regions of fusA, 
which encodes EF-G (Johanson & Hughes, 1994). A single mutation, F88L, has been 
identified as responsible for strong FSA resistance in S. aureus clinical isolates (Nagaev et 
al., 2001). This F88L mutation matches with the F90L mutation in Thermus thermophiles 
which also confers FSA resistance (Martemyanov et al., 2001). Studies have shown that the 
loss in fitness associated with FSA resistance is compensated by secondary mutations 
(Koripella et al., 2012). By characterizing three S. aureus EF-G mutants, Koripella et al 
reported that fitness defects in FSA-resistant mutants led to a significantly slower tRNA 
translocation and ribosome recycling. There was also an increase in peptidyl-tRNA drop off. 
The F88L mutant protein exhibited this defective function, whereas M16I showed high 
activity and hypersensitivity to FSA. Therefore, a direct correlation between fitness, caused 
by EF-G translocation and recycling, and FSA sensitivity was demonstrated (Koripella et al., 
2012). Resistance to FSA may also arise due to plasmid-mediated alterations in cell 
wall/membrane permeability. The type I chloramphenicol acetyltransferase (CAT-I), found in 
Enterobacteriaceae, can also inactivate FSA by competitively binding the drug and 
sequestering it (Marcoli, Iida & Bickle, 1980; Turnidge & Collignon, 1999).
 
Finally, although very limited data have been published on FSA combination studies, 
Phee, et al. reported robust synergy between FSA and colistin against a panel of multidrug-
resistant Acinetobacter baumannii  clinical strains including some colistin-resistant strains. 
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Here, synergy was evaluated in vitro against 11 multidrug-resistant A. Baumannii isolates. 
Synergy was demonstrated against all strains, with an average fractional inhibitory 
concentration index (FICI) of 0.064. Furthermore, time-kill assays showed that colistin-FSA 
was synergistic and rapidly bactericidal, including against colistin-resistant strains (Phee et 
al., 2015). Myint et al. also reported the synergistic interaction between FSA and the 
phytochemical tannic acid, against the three clinical strains of  methicilin-resistant S. aureus 
Moreover, the possible mechanism could be as a result of the phytochemical tannic acid 
potentiating the effect of FSA and/ or acting as alternative target that results in the lysis of 
bacteria (Myint, Sing & Wei, 2013). In mycobacteria, Hoffner et al reported synergistic 
interactions with EMB. Out of the 17 Mycobacterium avium complex strains studied, a 
combination of FSA and EMB exhibited synergistic effects against 11 strains  (Hoffner et al., 
1990) In addition, Ramon-Garcia and co-workers reported the combination between FSA and 
SPC as synergistic, FICI value = 0.25, against M. smegmatis (Ramon-Garcia et al., 2011). 
In summary, the in vitro effect exhibited by FSA against M. tuberculosis, its unique 
mechanism of action― specifically, inhibition of bacterial protein synthesis by binding to EF-
G, the antimicrobial-potentiating effect with other antibiotics including the anti-TB drug, 
EMB, as well as lack of cross-resistance to other antimicrobial classes inspired its choice as a 
classic repurposing agent for the synergistic drug interaction study  against both wild-type  
and multidrug- resistant strains of M. tuberculosis.  This work, therefore, fits as part of a 
larger project that explores the activity of FSA and/ or analogues in an effort to identify 
potential anti-tuberculosis drugs. 
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FSA analogues 
Drug repositioning (see section 1.4.3) has continued to play a key role in drug discovery. 
This strategy has resulted in analogues with one or several characteristics separating them 
from their progenitors; improved in vitro or in vivo efficacies,  no cross resistance with earlier 
antibiotics or a wide-spectrum of bacteria that are susceptible to the new molecule (Rolinson, 
1998). The structure-activity relationships of FSA has extensively been studied and large 
number of FSA analogues synthesised (Von Daehne, Godtfredsen & Rasmussen, 1979; 
Duvold et al., 2001). However, only a few of these analogues have exhibited activities 
comparable with that of  FSA . Most of these have similar antibacterial spectrum and are 
cross-resistant (Duvold et al., 2001). Four stereoisomers were prepared by reducing the 
double bond between C-17 and C-20 to explore the side chain which had not been previously 
explored. It was found that one stereoisomer (17S,20S), Figure 1-25 was equipotent to FSA 
out of four  
Figure 1-24 An overview of structure activity relationships of fusidic 
acids showing important and essential structural and functional 
features. (Adopted from Duvold, Tore 2001). 
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stereoisomers (17R,20S), (17R,20R), (17S,20S), (17S,20R) while others had low or no 
antibacterial activity when compared to FSA. Yet, an interaction study of the antibiotic [
3
 H]-
24,25-dihydrofusidic acid, an active analog of FSA , with the ribosome . EFG . GDP complex 
revealed the following (Willie et al., 1975b). (1) All components of the complex are essential 
for the [
3
 H]-24,25-dihydrofusidic acid binding, (2) the C17-20 double bond of fusidic acid was 
critical for both binding and complex stabilization activitities. (3) Modifications of other 
functional groups in the molecule could result in a significant decreased stabilization of the 
ternary ribosome complex and /or ability to compete with the [
3
 H]-24,25-dihydrofusidic acid 
for binding to the complex, but do not demonstrate absolute structural requirements for either 
activity. 
 
1.5. Antimicrobials and combination strategies 
Increased knowledge of the biology of a disease as a perturbed system comprising a network 
of molecular pathways that are more susceptible to simultaneous action of several drugs 
provides scope for rational development of combination therapies (Smalley et al., 2006; 
Podolsky & Greene, 2011).
  
Various factors can explain why a drug combination may have a 
particular effect. Key to this is the molecular interaction profiles of the constituent drugs, 
which describe their individual interactions with biomolecules, pathways or processes (Jia et 
Figure 1-25  17S,20S-dihydrofusidic acid 
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al., 2009). Other factors include genetic variations (Kim & Fay, 2007), environmental factors 
(Carvalho-Netto et al., 2006), host behaviour (Yang et al., 2012) and drug scheduling 
(Tabernero et al., 2008). Drug combinations are considered pharmacodynamically 
synergistic, additive or antagonistic if the elicited effect is greater than, equal to, or less than 
their summed effects (Chou, 2006). Coalistic combination occurs when all drugs involved are 
inactive individually but become active when combined (Greco, Bravo & Parsons, 1995). 
This kind of interaction may result, for example, when the expression of a target gene 
requires that two transcription factors each need to bind, with each constituent intervention 
activating one transcription factor only (Jia et al., 2009). 
Synergistic drug combinations have been utilized to achieve one or more of the 
following desirable outcomes: shortened therapeutic duration, decreased dosage at equal or 
increased efficacy, reduced or delayed development of drug resistance, and simultaneous 
enhancement of therapeutic actions as well as reduction of unwanted action (Kitano, 2007; 
Zimmermann, Lehar & Keith, 2007). Bhusal et al reported the use of a three-dimensional 
checkerboard assay to quantitatively determine antimycobacterial synergy. In addition, using 
this assay, they showed that ﬂuoroquinolones and antibacterial agents such as CLR are 
effective against multidrug-resistant isolates of M. tuberculosis when combined with RIF and 
INH (Bhusal, Shiohira & Yamane, 2005). In addition, Chen and co-workers employed an 
invitro BACTEC 460 system, that evaluated drug interactions based on the quotient values 
that were derived numerically from the growth indices of cultures treated with a single 
antibiotic or combination treatment with two antibiotics (Chen, 2006). These results 
suggested that  SQ109 at 0.5 of its MIC demonstrated strong synergistic activity with 0.5 
MIC INH and as low as 0.1 MIC RIF in inhibition of M. tuberculosis growth  (Chen, 2006). 
Rodriguez et al., also reported on the in vitro activity against M. tuberculosis of the 
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combination of fluoroquinolones and LZD with classical drugs. The combination of INH 
with fluoroquinolones had synergic activity in nine of the ten INH-susceptible strains. 
Furthermore, they reported synergism between RIF and LZD in five of the 15 strains 
susceptible to RIF (   az, Juan Carlos Rodriguez 2003) 
 
1.5.1. In vitro combination testing techniques 
There are different methods which have been developed to determine the in vitro activities of 
drug combinations against bacteria (Kurien & Lorian, 1980). These include the checkerboard 
technique, and serial broth dilutions of fixed proportions of the combined drugs (Garrod & 
Waterworth, 1962) Other methods include time-kill assays with the broth media, agar dilution 
method, paper-strip and double-disk agar diffusion with agar media (Hartkoorn et al., 2014; 
Willie et al., 1975). Checkerboard and time-kill assays have been reliably used in most 
antimicrobial experiments (Odds, 2003). 
 
(i) Checkerboard assays 
The checkerboard method is normally carried out in microtitre culture plates. In a standard 
two-drug combination, the first drug (drug A) is serially diluted along the ordinate and the 
second drug (drug B) along the abscissa. The result is that each well in the plate contains a 
unique combination of the two drugs being tested. The effect resulting from the combination 
of the two drugs is interpreted using the fractional inhibitory concentration index (FICI). This 
is defined as the sum of the fractional inhibitory concentration (FIC) of drug A (FICA) + FIC 
of drug B (FICB), where FICA is the minimum inhibitory concentration (MIC90) of drug A  in 
the combination (MICA(comb)) as a proportion of the MIC of drug A alone (MICA), and the 
FICB is MICB(comb))/ (MICB). A FICI ≤ 0.5 is interpreted as synergistic,  FICI > 0.5 but ≤ 4 is 
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considered as no interaction, and a FICI > 4 is designated as antagonistic (Odds, 2003; 
Johnson et al., 2004). In order to perform combinations of three antibiotics, a standard 
checkerboard titration of the two agents was adopted and modified (Bhusal, Shiohira & 
Yamane, 2005; Berenbaum, 1978). Herein, the third antibiotic was dispensed throughout the 
wells as an overlay at subinhibitory concentrations and synergistic interactions analyzed as 
already described with the two-drug combinations 
                          
                            Figure 1-26 Isoboles for synergistic, antagonistic or no interaction.  
                             (Adopted and modified from Cuenca-Estrella, 2004). 
 
Isobolograms have been used for the evaluation of drug interaction effects (Loewe, 1953). 
The calculated FICs, from the experimental data for agents used alone and in combination at 
equi-effective level, are plotted as shown in Figure 1-26. A combination is said to have no 
interaction if the data points are on the straight line connecting the FICs of drugs A and B at 
the X - and Y-axis intersections, respectively (Sühnel, 1990). Points below this line indicate 
synergy, while those above the line indicate an antagonistic interaction (Sühnel, 1990). 
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(ii)Time-kill curves 
The checkerboard assay is relatively easy to perform but provides only the inhibition data. In 
contrast, time-kill curves are more dynamic and provide a measure of bactericidal activity 
(Mueller, de la Pena & Derendorf, 2004).  However, limited concentrations can be tested at a 
given time owing to the number of tubes required. Therefore, a prior knowledge of test 
concentrations is necessary (Lorian, 2005). In time-kill assays, flasks containing broth media 
are inoculated with about 10
5 
-10
6
 colony-forming units (CFU/ml) of the test organism. 
Antibiotics are added to the flasks alone and in combination at relevant concentrations. The 
flasks are incubated and samples removed at set time intervals to determine the number of 
viable bacteria. Synergism is defined as ≥ 2log10 decrease in colony count of the combination 
compared with that of the more active drug tested alone, and as ≥ 2log10 decrease in colony 
count below the starting inoculum. A < 2log10 change (increase or decrease) in colony count 
compared to that of the most active drug tested alone is interpreted as no change or 
indifference, whereas ≥ 2log10 increase in colony count compared with that of the most active 
drug tested alone shows antagonism (Entenza & Moreillon, 2009). 
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1.5.2. Drug combinations: interaction mechanisms and selection against resistance 
Drug combination studies may reveal different mechanisms that result in synergism against 
bacteria. It is therefore important to characterize the underlying mechanisms of drug 
interactions, which are still largely unknown. In many cases, the individual modes of action 
(MOAs) of each drug cannot explain observed drug interactions in an obvious way 
(Ankomah, Johnson & Levin, 2013). Drug interactions leading to synergy can be as a result 
of a simple uptake effect, in the sense that an increase in permeability by one drug may cause 
accumulation of the other, hence synergy. Such an uptake effect has been shown with 
interactions between aminoglycosides and ß-lactam antibiotics (Plotz & Davis, 1962). In their 
study, Plotz and Davis showed that synergism of PEN with STR ensue from cell membrane  
damage by PEN resulting in further destruction by STR. This effect promotes subsequent 
access of PEN to intracellular sites (Plotz & Davis, 1962). Drug interactions can also result 
from direct physical interactions between the drugs at their target― a mechanism that has 
been observed for the antibiotics quinupristin and dalfopristin, (Figure 1-27) which bind to 
Quinupristin 
Dalfopristin 
Figure 1-27 Quinupristin and Dalfopristin 
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the ribosome at different sites and jointly stabilize their binding (Yonath, 2005). The 
interaction between these two drugs reveals a unique bactericidal mechanism of action 
(Vannuffel & Cocito, 1996). Dalfopristin, an olefinic macrolactone, binds to the 50S subunit 
of the prokaryotic ribosome. This results into (i) inactivation of the donor and acceptor sites 
due to interference with the peptidyl tranferase enzyme, and (ii) change in ribosome 
conformation, leading to an increase in the affinity of quinipristin, a peptidic macrolactone, 
which also binds to the 50S subunit. Quinipristin binding halts peptide chain elongation. The 
action of both of these drugs together permanently halts protein synthesis, leading to a 
synergistic and bactericidal activity, which is concentration-independent. In contrast, their 
action individually only causes a transient halt in protein synthesis, consequently resulting in 
a bacteriostatic effect (Cocito et al., 1997; Porse & Garrett, 1999).   
Interactions between bactericidal and bacteriostatic antibiotics have long been 
theorized to be generally antagonistic since killing by bactericidal antibiotics often requires 
cell growth, which is prevented by bacteriostatic drugs (Jewetz et al., 1952). There are other 
drug interactions that have more complex causes when the drugs perturb cell physiology and 
cause cellular responses subsequently affecting the activity of other drugs. (Bollenbach, 
2015). Nichols et al, have shown that the synergistic interaction between SMX and TMP is as 
a result of the two drugs targeting the tetrahydrofolate (THF) biosynthesis pathway (Nichols 
et al., 2011). In that study, the authors compared the growth of a library of E. coli deletion 
mutants in the presence of the two drugs, which target sequential steps in folic acid 
biosynthesis, namely dihydrofolate reductase and dihydropteroate synthetase, respectively. 
Based on their findings, they provided evidence that the synergism between these two drugs 
was partially caused by secondary effects on parallel branches of this pathway, downstream 
   41 
 
 
from the main targets (Nichols et al., 2011). Consequently, these effects augment synergism 
that is expected from inhibiting the drug’s primary target (Harvey, 1978). 
The impact of drug combinations on the differential selection between sensitive and 
resistant bacterial populations has been evaluated. Exposure of a bacterial population to a 
drug usually confers an advantage any resistant mutants in competition with the wild-type 
population (Levy & Marshall, 2004). By applying a direct competition assay between 
doxycycline (DOX)-resistant and DOX-sensitive Escherichia coli, Chait et al. showed that 
this differential selection can be upended with the hyper-antagonistic class of drug 
combinations (Chait, Craney & Kishony, 2007). In this kind of combination, and at sub-lethal 
concentrations, a drug can render the combined treatment to be selective against it its own 
resistant mutants while maintaining inhibition of the wild-type (Chait, Craney & Kishony, 
2007). 
 
1.6. Antimycobacterial potency of compounds: cidal versus static drugs. 
Antibacterial agents are often tested in vitro not only for their ability to inhibit bacterial 
growth but also to ascertain if the agents actually kill the bacteria (Pankey & Sabath, 2004). 
Although it would be preferable to kill pathogenic bacteria as opposed to inhibiting their 
growth, clinical outcomes provide the ultimate guide to the treatment of the infection (Pankey 
& Sabath, 2004). The target, therefore, should be achievement of good clinical outcomes, 
with clinical/bacteriological cure and no relapse and minimal toxicity (Pankey & Sabath, 
2004). In terms of the definitions, “bacteriostatic” refers to those agents which prevent the 
growth of the bacteria - that is, those that prevent an increase in biomass through cell division 
- while the term “bactericidal” refers to agents that actually result in bacterial death, which is 
complete loss of function without capacity for regeneration. In reality, however, this 
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classification of bactericidal versus bacteriostatic drugs is problematic. Agents classified as 
“bactericidal” normally fall short of killing every organism, for instance due to the inoculum 
effect, or as a consequence of persister cells. On the other hand, “bacteriostatic” agents may 
often kill a certain proportion of the population, but not large enough to be called 
“bactericidal” (Pankey & Sabath, 2004). 
 Many factors influence the in vitro determination of bactericidal or bacteriostatic drug 
effects including growth conditions, bacterial density, test duration, and extent of reduction in 
bacterial numbers (Peterson & Shanholtzer, 1992). In bactericidal test determination, 
antibiotic tolerance presents a particularly difficult form of resistance to detect from the 
perspective of the clinical laboratory (Tuomanen, Durack & Tomasz, 1986). While 
‘resistance’ is used to describe the inherited ability of microorganisms to grow at high 
antibiotic concentrations, irrespective of the duration of treatment, ‘tolerance‘ describes the 
ability, whether inherited or not, of microorganisms to survive transient exposure to high 
concentrations of an antibiotic without a change in the MIC (Brauner et al., 2016). In 
antibiotic tolerance, bacteria evade only the killing action of an antibiotic (Tuomanen, Durack 
& Tomasz, 1986; Brauner et al., 2016). Phenotypic tolerance may arise in cells without 
sufficient nutrients, which characteristically multiply slowly or do not grow, such as evident 
with the β-lactams (Peterson & Shanholtzer, 1992). As β-lactams require active cell wall 
assembly to kill bacteria, slower growth will result in a longer minimum treatment duration to 
achieve the same level of killing regardless of the concentration of the antibiotic (Brauner et 
al., 2016). 
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1.6.1. In vitro evaluation methods for bactericidal versus bacteriostatic drugs for M. 
tuberculosis 
A number of available screening systems such as BACTEC-TB 460 and MGIT-TB 960 are 
used for quantitative analysis of antibacterial susceptibility in M. tuberculosis. However, 
these methods are not high-throughput and require specialized instruments and media. High-
throughput assays such as Microplate Alamar Blue Assay (MABA) and the Resazurin-based 
Microplate Assay (REMA) are routinely applied to provide MIC information, but these do 
not provide a measure of the cidality of test compounds. In addition, reporter-based assays, 
such as luciferase (lux), or green-fluorescent protein (GFP) require modifications for each 
strain. None of these strategies has been shown to select bactericidal compounds (Franzblau 
et al., 2012). Instead, the gold standard test of “true” cidality remains the cumbersome, agar-
based colony forming unit (CFU) enumeration screens (Gilchrist et al., 1973). The following 
two methods have been reported for rapid evaluation in cidal versus stasis experiments 
(Zhang et al., 2007; Ramon-Garcia et al., 2011; Hendon-Dunn et al., 2016).  
 
(i) Cell regrowth assay (MBC/MIC) analysis: Zhang et al. investigated the fungicidal versus 
fungistatic activity of small molecule combinations using a cell regrowth assay (Zhang et al., 
2007). This technique was adopted to differentiate bactericidal or bacteriostatic effects of a 
single drug or drug combination against M. tuberculosis (Ramon-Garcia et al., 2011; Ramon-
Garcia et al., 2012). In that study, a drug panel consisting of CLR, ketoconazole, 
bromperidol, RIF, and INH (a positive control), individually and as a combination with SPC, 
were tested in vitro to determine whether they were bacteriostatic or bactericidal. A 
compound or drug combination was considered bactericidal if the ratio between the minimal 
bactericidal concentration (MBC) and the MIC was equal to or smaller than 2 (MBC/MIC ≤ 
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2). The reported results for the individual drugs indicated bactericidal activity with INH and 
bromperidol. Furthermore, an assay of SPC, a bacteriostatic drug, in combination with the 
sub-MIC concentration of bromperidol revealed a bactericidal activity, suggesting that the 
bactericidal character of bromperidol was dominant in the combination. The same effect was 
not observed when SPC was combined with ketoconazole, CLR, or RIF (Ramon-Garcia et 
al., 2011). 
 
(ii) Flow cytofluorometric method: The usefulness of this technique has been investigated by 
many authors for antibacterial and antifungal analysis (Green et al., 1999; Ramani & 
Chaturvedi, 2000; Paparella et al., 2008). Using a rapid dual-fluorescence flow cytometry 
method, Hendon-Dunn et al. recently demonstrated that the fluorescent marker, Calcein 
Violet-AM (CV-AM), could differentiate between populations of M. tuberculosis bacilli 
growing at different rates, while SYTOX-green (SG) could differentiate between live and 
dead mycobacteria (Hendon-Dunn et al., 2016). Paparella et al. earlier reported the usefulness 
of this technique to discriminate clearly between three different subpopulations of Listeria 
monocytogenes: viable, dead and injured cells following treatment with different types of 
essential oils  (Paparella et al., 2008). 
 
1.7. Research Objectives 
The main objective of this research was to explore the potential of synergistic drug 
combinations, focusing on drug repurposing, as a strategy for the identification of potential 
TB drug combination partners. The concept behind this work stems from previous studies 
which have shown that antibiotics that are currently in clinical use, but have limited efficacy 
against M. tuberculosis, could be used in TB treatment when administered in combination 
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with standard anti-TB drugs. To test the potential of combination screening approaches to 
drug repurposing for TB drug discovery and development, this research focused on the 
clinically used natural product antibiotic FSA and its selected analogues. 
 
1.7.1. Specific objectives 
 1) Develop screening assays for the identification of synergistic drug interactions between 
FSA in combination with standard anti-TB drugs and selected translational inhibitors. 
2) Determine the extent to which synergistic drug combinations can overcome pre-existing 
drug resistance. 
3) Perform a novel 3-drug combination assay to determine the potential of including a third 
drug into RIF-INH; two main-stay TB treatment regimens.  
4)  Develop methods to delineate the bactericidal/bacteriostatic effect of antibiotics against 
mycobacteria. 
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Chapter 2  
The search for synergy: Interaction of FSA in combination with anti-TB agents and 
selected translational inhibitors. 
2.1 Background 
Drug combinations have been widely envisaged as a promising strategy in the treatment of 
various diseases including cancer, malaria and tuberculosis (TB) (Caminero, 2010). Within 
this context, synergistic drug combinations have resulted in more efficacious and specific 
therapies (Lehár et al., 2009). In addition, cases of drug resistance emerging during therapy 
have been greatly reduced (Owens et al., 2013). For example, it has been shown that synergy 
results in rapid clearance of the infection thereby decreasing the time in which resistant 
mutants can occur (Torella, Chait & Kishony, 2010).  A study by Lehar et al. further 
underpinned the use of drug combinations as a promising strategy to overcome the make-up 
mechanisms and unwanted off-target effects that limit the utility of many potential drugs. 
Results from large-scale simulations of bacterial metabolism and several multi-dose 
experiments suggested that synergistic drug combinations were generally more specific to 
particular cellular contexts than are single agent activities. Besides, selectivity with these 
combinations was achieved as a result of  the differential expression of the drug’s target in 
the cell types associated with therapeutic, but not toxic, effects (Lehár et al., 2009). This 
finding tempers the concern that the therapeutic synergy of a combination will be 
accompanied by synergistic side effects (Lehár et al., 2009). Despite reported success with 
combination screening, including the current TB drug regimen, very few systematic studies 
have been undertaken to show how these drugs interact with each other. Furthermore, very 
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little attention has been paid to exploring synergistic interactions involving drugs which are 
not clinically effective against TB (Ramon-Garcia et al., 2011). 
As a drug repurposing strategy, we focused on FSA to develop matrix screening 
assays aimed at identifying optimal drug combination(s) that might be considered within the 
existing TB drug pipeline for potential clinical efficacy evaluation. More than that, the 
essence of this work was to explore the potential of synergistic drug interactions and 
demonstrate the integral role played by synergy towards realizing successful therapeutic 
outcomes. This chapter presents the analysis of in vitro interactions between FSA and a panel 
of drugs consisting of agents currently used in TB treatment as well as selected translational 
inhibitors. The latter were prioritized in this study in order to evaluate the outcome of their 
combination with FSA since they act on the same pathway (Figure 1-7).  
2.2 Results 
2.2.1 Identification of synergistic drug combination partners for FSA 
A presumptive study was performed using M. smegmatis mc
2
155, a non-pathogenic 
mycobacterium whose genetic relatedness to M. tuberculosis and faster growth has identified 
this bacillus as a useful surrogate in drug efficacy studies in vitro, allowing assays to be 
completed within a shorter duration (Cordone et al., 2011). 
Checkerboard experiments using the selected panel of drugs exhibited either 
synergistic or no interaction combination profiles with FSA (Table 2.1). More specifically, 
SPC, ERY, CLR and TET exhibited synergy with FSA. Synergy was defined as FICI ≤ 0.5.  
No antagonistic effects were observed in any of the combinations tested. Those combinations 
which elicited synergistic interactions against M. smegmatis displayed a 4–16 fold reduction 
in the MIC for each of the individual drugs (Figure 2-1). 
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Table 2-1 In vitro synergistic interactions between fusidic acid (FSA) and anti-TB agents or 
selected translational inhibitors in M. smegmatis.  
Compound
a
 MIC
b
 
(µM)individual 
MIC
b
 
(µM)combined 
FIC FICI
c
 
FSA 
RIF 
81-162 20 0.12-0.25 
0.62-0.75 
10 5 0.5 
     
FSA 
INH 
162 81 0.5 
1.5 
13 13 1 
     
FSA 
EMB 
162 81 0.5 
0.75-1.0 
1.6-0.8 0.4 0.5-0.25 
     
FSA 
STR 
81 41 0.51 
0.71 
0.5 0.1 0.2 
     
FSA 
KAN 
81 81 0.51 
1.01-1.51 
4 2-4 0.5-1 
     
FSA 
OFX 
41 41 1 
2 
0.5 0.5 1 
     
FSA 
SPC 
81 5 0.06 
0.32 
50 13 0.26 
     
FSA 
ERY 
41 10 0.24 
0.49 
8 2 0.25 
     
FSA 
CLR 
81-162 20 0.12-0.25 
0.32-0.45 
5 1 0.2 
     
FSA 
TET 
81 10 0.12 
0.41 
0.7 0.2 0.29 
a
Compounds selected for this in vitro interaction assay included RIF, INH,  EMB, STR, 
KAN, OFX, SPC, ERY, CLR and TET. 
b
MIC90 was determined using the resazurin assay. MIC values were determined as the lowest 
concentration of each drug(s) that prevented colour change. 
c
The FICI values represent the lowest values taken from two  biological replicates. FICI ≤ 0.5 
synergy; 0.5<FICI ≤4 no interaction; >4 antagonistic. 
FICI values of drug combinations displaying synergy are shown in bold
. 
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On the basis of the synergies evident in M. smegmatis, further interaction studies were 
performed using the checkerboard method with an M. tuberculosis H37Rv reporter strain 
expressing green fluorescent protein (GFP); this strain has been used previously in high-
throughput antimicrobial drug screening (Srivastava et al., 1998). Figure 2-2 provides an 
example of an interaction study in which FSA and ERY were analysed in the checkerboard 
assay using M. tuberculosis::GFP. Representative drugs consisting of clinically used anti-TB 
agents (first- and second-line) and selected translational inhibitors were also tested in 
combination with FSA. Hits identified using M. smegmatis, except for TET owing to its 
unavailability at the time,  were also included for comparative 
analysis.
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Figure 2-1 MIC fold-reduction of combinations exhibiting in vitro synergistic 
interactions when tested against M. smegmatis  showing mean ± SD from duplicate 
samples.  
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Results in Table 2.2 show similarity to those obtained for M. smegmatis, such that SPC, ERY 
and CLR exhibited synergy with FSA in M. tuberculosis. As highlighted (Figure 2-2), the 
combination between FSA and ERY showed a FICI value of 0.25, suggesting a synergistic 
interaction. Other drugs that synergized with FSA included RIF, STR, roxithromycin (ROX), 
and LZD. These synergistic interactions resulted mainly in a 4- to 8- fold reduction in the 
MICs of each drug within the combination. Even though the combination of FSA and BDQ 
did not result in a FICI value of ≤ 0.5, it is important to note that the two displayed 
approximately a 4-fold reduction in their respective MICs, and the observed FICI (0.55) is 
very close to that defined as “synergy”. No antagonistic interaction was observed between 
FSA and any of the compounds tested. 
 
Figure 2-2 Checkerboard assay: Investigating the in vitro interaction between FSA and ERY 
against M. tuberculosis::gfp strain in a 96-well microtitre plate. Combinations with > 90% (blue) 
and < 90% inhibition (pink). MIC90 wells for both FSA and ERY are shown in white oval and the 
iso-effective concentrations from which FICs were calculated are indicated in yellow rectangles. 
The combination with the lowest FICI (i.e 0.25) is shown in green oval.   
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Table 2-2 In vitro synergistic interaction between fusidic acid FSA and anti-TB agents or 
selected translational inhibitors against M. tuberculosis::gfp 
Compound
a
 MIC90
b
 
(µM)individual 
MIC90
b
 
(µM)combined 
MIC90fold-
reduction 
FIC FICI
c
  
FSA 
RIF 
2.5 0.61 4 0.24 
0.48 
 
0.003 0.0008 4 0.24  
       
FSA 
INH 
2.4 1.2 2 0.50 
1.00 
 
0.6 0.3 2 0.50  
       
FSA 
EMB 
2.4 1.2 2 0.50 
1.00 
 
2.5 1.25 2 0.50  
       
FSA 
STR 
2.4 0.6 4 0.25 
0.50 
 
0.4 0.1 4 0.25  
       
FSA 
AMK 
2.4 1.2 2 0.50 
0.94 
 
0.9 0.4 2 0.44  
       
FSA 
OFX 
2.4 2.4 1 1.00 
1.30-1.50 
 
1.4-2.8 0.7 2-4 0.25-0.5  
       
FSA 
SPC 
2.4 0.3 8 0.13 
0.26 
 
201 26 8 0.13  
       
FSA 
ERY 
2.4 0.3 8 0.13 
0.25 
 
217 27 8 0.12  
       
FSA 
CLR 
4.6 0.7 7 0.15 
0.30 
 
2.0 0.3 7 0.15  
       
FSA 
GAT 
2.4 0.6 4 0.25 
0.73 
 
2.1 1.0 2 0.48  
       
FSA 
ROX 
2.4 0.6 4 0.25 
0.50 
 
3.6 0.9 4 0.25  
       
FSA 
BDQ 
5.0 1.3 4 0.26 
0.55 
 
1.4 0.4 4 0.29  
       
FSA 
LZD 
4.8 1.2 4 0.25 
0.50 
 
1.4 0.4 4 0.25  
       
FSA 
CYC 
1.4 0.6 2 0.43 
0.93 
 
196 98 2 0.50  
a
Compounds selected for this in vitro interaction assay included rifampicin (RIF), isoniazid (INH), 
ethambutol (EMB), streptomycin (STR), kanamycin (KAN), ofloxacin (OFX), spectinomycin (SPC), 
erythromycin (ERY), clarthromycin (CLR), gatifloxacin (GAT), roxithromycin (ROX), bedaquiline 
(BDQ), linezolid (LZD) and cycloserine (CYC). 
b
The  FICI values represents the lowest values taken 
from two  biological replicates  FICI ≤ 0.5 synergy; 0.5<FICI ≤4 no interaction; >4 antagonistic. 
*Values representing synergistic interactions are shown in bold. 
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Figure 2-3 Isobolograms of FSA versus selected partner compounds. FIC curves of FSA versus (A) 
ERY (B) STR (C) ROX (D) CLR (E) SPC (F) RIF) (G) LZD (H) INH control drug. Synergy region (FICI ≤ 0.5) 
is defined by the red square. Data are representative of two biological replicates. 
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For the combinations exhibiting synergy with FSA, isobolograms were constructed by 
plotting the FIC curves of the FSA-drug combinations (Figure 2-3). Interactions between 
FSA and SPC, CLR and RIF were well within the ‘synergy region’ (FICI < 0.5) whereas FSA 
with STR, LZD, and ROX indicated borderline synergy (FICI = 0.5). The FSA-INH 
interaction was included as a reference for a no interaction drug combination.  
Time-curve Assay: The time-curve study was used to confirm results obtained using 
the checkerboard assay. In time-curve, FSA and ERY, a combination that exhibited potent 
interaction, was evaluated, (Figure 2-4). FSA and ERY were used at 0.3 and 27 µM 
respectively, since these are the concentrations at which the lowest FICI value was displayed 
in the checkerboard assay (Figure 2-2). RIF, at a concentration of 0.015 µM, was included as 
a control. In the absence of drug, the population of M. tuberculosis increased over 14 days 
post-inoculation. In contrast, the population of viable cells remained relatively constant over 
the same duration when the broth contained the FSA and ERY combination. Similarly, the 
test broth that contained FSA, ERY plus sub-MIC RIF did not display any increase in the 
number of viable bacterial population over a 14-day period. However, the broth containing 
individual antibiotics (FSA or ERY) showed equivalent growth to the untreated control. 
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2.2.2 Assessing synergistic and peak plasma concentrations (Cmax) as well as cLogP 
values of FSA synergizing drugs for optimal therapy. 
As a key consideration for the clinical potential of FSA combinations, the respective 
concentrations at which synergy was observed were compared with the reported peak plasma 
concentrations (Cmax) for each drug. This is important in understanding whether or not the 
concentrations required to achieve the desired response are therapeutically feasible – in the 
absence of such knowledge, investigating combinations might be criticized as representing an 
academic exercise. 
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Figure 2-4 Kinetic Assay.  Time-curve experiments for FSA, ERY and RIF alone and in 
combination. Viable cell concentrations in culture broth at the indicated time were 
determined on Middlebrook 7H10 agar. CFU, colony forming units. Data are from a single 
experiment only, owing to limited compound availability. 
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Except for the FSA-ERY interaction, synergies between FSA and its partners were achieved 
at concentrations predicted to be below the maximum plasma concentrations, suggesting that 
these concentrations are therapeutically achievable, (Figure 2-5). For example, the presence 
of FSA decreased the MIC of SPC from 201 µM to 3.14 µM, which represents a greater than 
98% reduction in the MIC (Table 2.3). This reduced concentration is far below the Cmax value 
of SPC in humans (30.8 µM) after a 1000- mg intramuscular dose.  
Apart from the peak plasma concentrations, it is noteworthy that the site of many 
infectious diseases is outside the blood or plasma compartment. In TB for example, the 
mycobacteria can reside in caseous lesions that are devoid of vascular supply, thus impacting 
any drug’s ability to be effective against the pathogen at the site of infection.   
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Figure 2-5 Synergy vs Cmax. Comparison between synergistic concentrations of various drugs in 
the presence of FSA and their published Cmax values. With the exception of ERY, all drugs - SPC, 
CLR, RIF,ROX, LZD, and STR - exhibited synergistic concentrations lower than their known Cmax  
values. *Synergistic concentration values obtained from a representative experiment performed 
in triplicate. **Cmax values from literature (Lee,R.E. 2014; Mensa,B. 2011).  
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Table 2-3 Reduction of MIC following addition of FSA at sub-inhibitory concentrations 
Antibiotic 
a
 MIC90 (µM) % MIC90 
reduction 
b
Peak plasma 
concentration 
(µM) 
 -FSA 
c
+FSA   
ERY 217 27 87.6 20.4 
CLR 1.3 0.08 93.8 323 
SPC 201 3.14 98.4 30.8 
RIF 0.003 0.0008 73.3 24.3 
ROX 3.55 0.09 97.5 8.12 
LZD 9.9 2.5 74.7 19.6 
STR 0.4 0.1 75 41.2 
a
MICs of synergizing partner drugs in the absence (-) and presence (+) FSA.     
b
Literature 
Cmax values for the respective drugs (Lee et al., 1977; Mensa et al., 2011)  
c
Sub-inhibitory 
concentrations  of FSA that exhibited the respective synergies  in these checkerboard 
experiments  are between (0.3 – 1.2 µM) 
 
Recent work has shown that the octanol-water partitioning coefficient, also referred to as 
lipophilicity (cLogP), is likely to play an important role in determining caseum penetration 
(Sarathy, Jansy P 2016). .As a drug’s lipophilicity increases, non-specific protein binding also 
increases. This consequently results in a reduced free fraction to passively diffuse through the 
caseum, and an increase in intracellular macrophage permeation due to uptake of protein-
drug complex through such means as endocytosis and lysosomal trapping (Prideaux et al., 
2015). Therefore, the cLogP values of FSA synergizing drugs were examined in relation to 
other drugs including PZA, a drug that achieves excellent sterilizing activity of extracellular 
anaerobic bacteria (Prideaux et al., 2015); RIF, which has previously been shown to balance 
between relatively low uptake into macrophage and ideal caseum binding leading to 
continued build-up into the necrotic core; and clofazimine (CFZ), which does not diffuse into 
the necrotic core due to its high  lipophilicity. A quadrant model (Figure 2-6) was generated 
that relates the potency of these synergizing drugs when combined with FSA to their 
respective cLogP values. This understanding enabled us to hypothesize the action of the drug 
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combinations at the two phases - the cellular macrophage and the avascular caseum - which 
are considered critical to determining sterilizing action. 
 
 
 
Considering RIF as a reference for “desirable” cLogP values, drugs with low cLogP values 
would generally be expected to exhibit greater accumulation into the necrotic core whereas 
the more lipophilic compounds would spatially distribute within the cellular macrophages. 
Thus, a combination comprising high potency and low lipophilicity is preferred for targeting 
the extracellular (anaerobic) bacteria residing inside the caseum. From our plot, all the drugs, 
which synergized with FSA were spatially distributed within the ‘desirable’ quadrant. This 
suggests their potential as sterilizing agents for caseum bacilli. 
Figure 2-6 A comparison of cLogP value vs FICI for FSA synergizing drugs (in green), and 
selected reference drugs (RIF, CFZ and PZA). 
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2.2.3 A cidal versus static analysis of FSA interactions  
To determine whether or not FSA interactions resulted in killing or merely inhibited the 
growth of M. tuberculosis, the method of Zhang et al. was utilized (Zhang et al., 2007). INH, 
a bactericidal agent, was used as a reference drug.  The drugs were tested alone and in 
combination using the M. tuberculosis H37Rv::gfp strain. Results for the bacteriostatic or 
cidal effects of the drug combinations with FSA are illustrated, (Figure 2-7). The FSA-RIF 
combination displayed a MBC/MIC ratio of 1-2 on day 14 of evaluation, suggesting cidality. 
The other FSA combinations tested – with SPC, ERY, CLR, ROX or LZD – all exhibited a 
MBC/MIC ratios >2, implying static effects. The bacteriostatic/cidal action of individual 
drugs is shown below (Figure 2-8). 
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Figure 2-7 Bactericidal versus static effects of drug combinations against M. tuberculosis. Analysis of 
FSA in combination with synergizing drugs; ERY, SPC, CLR, ROX, RIF, and LZD. INH was used as 
reference drug. MBC/MIC ratio 1-2: cidal;  MBC/MIC ratio > 2:   static.  
*Sub-inhibitory concentrations  of FSA that exhibited the respective synergies  in these checkerboard 
experiments  are between (0.3 – 1.2 µM) Data are from a representative experiment performed in 
triplicate. Error bars indicate standard deviations, calculated from the mean of triplicate samples. 
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2.2.4 FSA synergizing partners are active against the FSA-resistant mutant. 
A cross-resistance study was undertaken using a FSA-resistant fusA1 mutant strain of M. 
tuberculosis H37Rv. The fusA1 mutation was selected as a spontaneous FSA-resistance 
mutation in EF-G, H462Y. Briefly, this mutant was generated by plating 10
9
 CFU per plate in 
7H10/OADC. The colonies were isolated from 20X MIC plate. (Moosa, unpublished data). 
The FSA-resistant mutant exhibited a > 100-fold MIC compared to the FSA susceptible 
strain. Six FSA synergizing partners (RIF, SPC, CLR, ERY, STR and ROX) were evaluated 
using the resazurin reduction microplate assay (REMA). The results (Figure 2-9) indicated 
that the MIC90 values of these drugs remained the same against the FSA-resistant mutant 
relative to the wild-type strain, confirming that there was no cross-resistance to each of the 
tested compounds.  
Figure 2-8 Bactericidal-static assay. Bactericidal versus static effects of individual drugs against 
H37Rv::gfp.FSA,ERY, SPC,CLR,ROX, and RIF. INH was used as reference drug. MBC/MIC ratio 1-2 
cidal;  > 2  static. Data are from a representative experiment performed in triplicate. 
Error bars indicate standard deviations, calculated from the mean of triplicate samples. 
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Figure 2-9 Cross-resistance study. Investigating cross-resistance  of the FSA resistant mutant against 
FSA synergizing drugs. FSA  synergizing partners are tested (A) FSA (control drug)  (B) RIF (C) (CLR (D)  
(ERY) (E) STR (F) ROX (G) SPC.  Data are from the representative experiment  performed in triplicate. 
Error bars indicate standard deviations, calculated from the mean of triplicate samples. 
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Table 2-4  Selected chemically and structurally diverse drugs  
Compound Abbreviation Chemical 
classification 
Therapeutic 
use
a
 
Isoniazid INH Isonicotinyl-
hydrazide 
Antituberculosis 
Ethambutol EMB Ethylenediamine Antituberculosis 
Thiostrepton THS Cyclic 
oligopeptide 
Antibacterial 
Bedaquiline BDQ Diarylquinoline Antituberculosis 
Chlorpromazine CPZ Phenothiazine Antipsychotic 
Moxifloxacin MOX Fluoroquinolone Antibacterial 
a
From PubChem(http://pubchem.ncbi.nlm.nih.gov/) 
 
2.2.5 Interaction of FSA synergizing partners with selected chemically unrelated 
compounds 
Using a set of six chemically and structurally diverse drug agents (Table 2.4), a 
combinatorial assay was performed with four drugs that had displayed synergistic interaction 
with FSA, namely RIF, ERY, CLR and SPC. The aim was to determine whether these FSA 
synergizing partners displayed synergy only in combination with FSA, or were possibly 
associated with a wide spectrum of synergistic interactions. The results of these pairwise 
interactions (Figure 2-10) revealed synergy between all FSA synergizing partners (except 
RIF) with BDQ and CPZ. CLR, in particular, displayed strong synergies with BDQ and CPZ 
(FICI = 0.23 in both cases). The interaction between ERY and THS was also synergistic, 
while the remaining compounds (INH, EMB and MOX) exhibited no interactions in 
combination with RIF, ERY, CLR and SPC.   
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Figure 2-10 Drug interaction study.  Pairwise interactions between selected drugs (Drug X) and synergizing agents of FSA (Drug Y) using M. tuberculosis 
H37Rv::gfp. Green panels indicate synergistic interactions (FICI ≤ 0.5), while red panels are  no interaction ( 0.5 > FICI ≤ 4). The bars indicate the fold-
reduction in MIC required to achieve the same effect in combination versus single-drug assays. Panels with no bars indicate no change in MIC
90
 for the drug 
combination compared to their respective MICs when used alone. Data are from the representative experiment  performed in duplicate. 
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2.3 Discussion 
Using a combination of checkerboard and time-kill kinetic assays, seven drugs were 
identified that synergized with FSA in vitro. These include the rifamycin, RIF, and the 
macrolides, ERY, CLR, and ROX. Others included the oxazolidinone, LZD, the 
aminoglycoside, STR, and an aminocyclitol class compound, SPC. Moreover, the fold-
reduction in the MIC90 of the interacting drugs was demonstrated. As an example, ERY 
enhanced the potency of FSA to a much-reduced MIC of 0.3µM from 2.4 µM, representing 
an 8-fold reduction in the MIC90. Apart from the synergy observed, other two-drug 
combination results showed that most of the interactions had FICI values between 0.5 and 
4.0, indicating a no interaction effect. None of the combinations with FSA showed any 
antagonistic effects, FICI value ≥ 4.0. Validation of the synergy displayed between FSA and 
ERY using the checkerboard assay was achieved using the time-kill kinetics experiment. The 
reason for this FSA-ERY synergy remains unknown. However, a systematic study of drug 
interactions reveals that compounds inactivating the same cellular function act efficiently 
when combined (Yeh, Tschumi & Kishony, 2006). This might explain the observed synergy 
since ERY, and indeed other macrolides, targets the ribosome. ERY inhibits protein synthesis 
by binding to the 23S rRNA molecule, located in the 50S subunit of the bacterial ribosome, 
thereby blocking the exit of the nascent peptide chain (Gupta, Agarwal & Srivastava, 2014). 
On the other hand, FSA is presumed to target elongation factor G when in complex with the 
ribosome (Gao et al., 2009).This interaction might account for the synergy observed. 
A vital aspect to consider for the clinical utilization of (synergistic) drug combinations 
is whether or not the synergistic concentrations required for realizing an effective response is 
therapeutically achievable (Bruhn et al., 2015). Sufficient concentrations of the drug 
combinations in the blood stream and affected tissues are needed to achieve the desired 
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therapeutic effect (Winglee et al., 2015). If both drugs are present with the concentration of 
one of the drugs being lower than the concentration for synergy, this can result in a 
mismatched exposure where the bacteria are exposed to long periods of monotherapy. 
Consequently, the induction of transient resistance mechanisms may ensue, hence selection 
of genetic mutants (Drusano et al., 2010). The results demonstrated that synergies with FSA 
were achieved at concentrations lower than the respective peak plasma concentrations for all 
the drugs except ERY. In addition, all of the FSA synergizing drugs fitted into the “desirable” 
quadrant, suggesting their potential to access the caseum, a critical site of mycobacterium 
residence. When FSA synergizing partners were tested in combination with other chemically 
diverse agents, BDQ and CPZ exhibited the most promising synergistic interactions. The 
synergy with CPZ may be attributed to its efflux pump inhibitory effect, resulting in the 
accumulation of the partner compound (Winglee et al., 2015). Work from Weinsten et al has 
previously described the biochemical characterization of the aerobic respiratory chains from 
M. tuberculosis and shown that phenothiazine analogs specifically inhibit 
NADH:menaquinone oxoreductase activity (Weinstein et al., 2005). Therefore, it is possible 
that CPZ-mediated inhibition of energy metabolism might impact activity of the efflux pumps 
such as Rv1258c thereby conferring sensitivity to FSA. However, the mechanism responsible 
for synergistic interactions between BDQ and FSA synergizing partners,  requires further 
investigation. The possible hypothesis for this synergy may also be a result of deleterious 
effect caused by combining FSA with BDQ, the agent affecting energy metabolism. 
The challenge of overcoming antibiotic resistance continues even with the use of drug 
combinations. The bacteria can evolve resistance to one drug thereby risking the possibility 
that the bacteria will also be able to resist the other drug(s) in the combination regimen. An 
understanding of cross-resistance between drugs is an important first-step in determining the 
   65 
 
 
drug combinations that would provide effective therapy (Sanders et al., 2001). .Here, the 
cross-resistance studies showed a mechanism of resistance specific to FSA when compared to 
the tested drugs that synergized with it. Interestingly, FSA-resistant mutants exhibited 
increased susceptibility  to the inhibitory action of SPC and STR  at sub-MIC  concentrations. 
The significance of this susceptibility and the related mechanism is yet to be established. 
However, hypersusceptibility to different classes of antibiotics against FSA-resistant mutant 
of Salmonella typhimurium has earlier been reported (Macvanin et al., 2000). Moreover, it 
has been shown that fus A1 mutations, associated with FSA-resistance, have pleiotropic 
phenotypes that affects  the fitness of FSA-R mutants in vitro and in vivo (Macvanin et al., 
2000). Some or all of these phenotypes may be related to the down-stream effects of altered  
transcriptional regulators ppGpp and RpoS in FSA-R mutants (Macvanin & Hughes, 2005). 
In the case of norfloxacin, for example,  increased susceptibility parallels increased 
sensitivity to DNA damaging agents as seen with ultra-violet (UV) light. Thus one of the 
pathways of DNA repair may be under-expressed in the fus A1 strain (Macvanin & Hughes, 
2005). fus  A1 mutations associated with altered cell shapes might result to increased 
susceptibility to ß-lactam antibiotics (Macvanin et al., 2000; Macvanin & Hughes, 2005). 
Resistance to STR caused by mutations is very strongly associated with reduced affinity for 
its binding site on the ribosome (Bohman et al., 1984; Bilgin et al., 1992).. Therefore, it has 
(Bohman et al., 1984) been suggested that the hyper-susceptibility to STR associated with fus 
A1 might be due to mutant EF-G influencing access of the antibiotic to its ribosomal binding 
site.  
In view of these promising synergistic interactions, it would be important to carry out 
further larger scale in vitro combinations, ex vivo and follow-up in vivo experiments to 
evaluate the effect of these drug interactions against various clinical isolates as well as multi-
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drug resistant M . tuberculosis strains. In  large scale in vitro combinations, a  syncretic cross-
(or matrix) screening approach (Keith et al., 2005), has been utilized to uncover interactions 
involving off-patent (“re-purposed”) drugs inhibiting sphingolipid biosynthesis or modulating 
membrane permeability potentiating fluconazole against Candida and Cryptococcus (Spitzer 
et al., 2011). In addition, Small et al., applied a genetic algorithm (evolutionary computing) 
strategy to hone all possible combinations of probe drugs inhibiting the cellular release of 
cytokines down to the best combinations; this allowed for the simultaneous identification of 
the best targets as well as the best dose ratios to apply  (Small et al., 2011). 
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Chapter 3          
Developing synergistic combinations to restore drug sensitivity in drug-resistant 
Mycobacterium tuberculosis. 
3.1. Background 
In order to treat multi-drug resistant (MDR) tuberculosis effectively, drug regimens are 
required that not only affect essential cellular processes, but also act synergistically with each 
other. Therefore, it is important to prioritize combination therapies that extend beyond 
biologically active individual molecules. This chapter explores the potential use of more 
potent synergistic combinations to circumvent resistance emanating from individual drugs in 
combination therapies, even restoring susceptibility to compounds for which genetic 
resistance is present.  
Herein, the checkerboard assay was used to investigate the relationship between the 
inferred potency of drug combinations against wild-type, drug-susceptible M. tuberculosis (as 
determined by FICI) and activity against cognate drug-resistant mutants. Specifically, 
interactions with FSA, its semi-synthesized structurally modified analogues GKFA17, GKFA 
37, GKFA51 and GKFA61 (Figure 3-1) were investigated. Furthermore, the in vitro and ex 
vivo interactions between SPC, a drug that exhibited synergy with FSA and its analogues, and 
the standard frontline TB drugs, RIF and INH, were evaluated. This was carried out using a 
three-drug combination assay against both the susceptible and drug resistant M. tuberculosis 
strains. 
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The specific objectives for this chapter were to: 
1. Determine the potencies of FSA and selected analogues in combination identified FSA 
synergizing partner drugs. 
2. Establish a correlation between the potency of a combination and its efficacy against 
cognate resistant mutants. 
3. Investigate the potential of adding a third drug to the standard two–drug continuation 
regimen consisting of RIF and INH for treatment of susceptible and resistant M. tuberculosis 
strains. 
 
 
 
 
Figure 3-1 FSA and selected analogues 
Fusidic acid (FSA); 
MIC90 2.4 µM 
 
MIC90 2.4 µM 
GKFA 17; MIC90 4-17 µM 
GKFA 61; MIC90 13-27 µM 
GKFA 37; MIC90 2.4 µM 
GKFA 51; MIC90 2.3 µM 
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3.2. Results 
3.2.1. Synergistic interactions between analogues of FSA with selected partner 
compounds. 
This experiment, undertaken using the drug susceptible M. tuberculosis H37Rv, was 
performed to allow for the prioritization of synergistic interactions that would subsequently 
be tested on the resistant mutants. As highlighted, the study hypothesized that strong 
synergies against the wild-type strain would equally elicit greater inhibitory activity against 
the resistant mutant, even to the extent of restoring drug susceptibility. Four drugs - SPC, 
ERY, CLR and RIF - were selected based on previous results which suggested their 
synergistic interaction with FSA (Chapter 2 Table 2.2).  The in vitro synergistic assay was 
performed using these drugs in combination with FSA, GKFA17, GKFA37, GKFA51 and 
GKFA61 in checkerboard assays, from which isobologram curves were derived (Table 3.1, 
Figure 3-2). The combination of ERY or SPC with FSA yielded the lowest FICI values of 
0.15 and 0.18 respectively, suggesting strong synergy. SPC generally displayed lower FICI 
values, implying better synergistic interactions with the FSA and its analogues. All 
interactions assessed resulted in either synergistic (FICI ≤ 0.5) or no interaction, > 0.5 FICI ≤ 
4. No antagonistic interactions (FICI > 4) were observed with the compounds selected.  
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Table 3-1 Checkerboard assay. In vitro interaction of  FSA, its analogues GKFA17, 
GKFA37, GKFA51, GKFA61 vs (A) ERY (B) SPC (C) CLR (D)RIF against M. tuberculosis, 
H37Rv strain. Interaction is interpreted as synergy FICI ≤ 0.5; no interaction 0.5<FICI ≤ 4; 
antagonistic > 4. . Data are representative of two biological replicates. 
   Drug 
combination 
Compound MIC90 
(µM)individual 
MIC90 
(µM)combined 
FIC FICI 
A FSA/ analogues and 
ERY 
FSA 2.42 0.30 0.12 0.15 
 ERY 109 3.41 0.03 
       GKFA17 17 4.25 0.25 0.38 
 ERY 109 13.63 0.13 
       GKFA37 2.42 0.61 0.25 0.50 
 ERY 109 27.25 0.25 
      
 GKFA51 5.26 0.61 0.12 0.37 
 ERY 109 27.25 0.25 
       GKFA61 13.87 3.47 0.25 0.50 
 
 
 
 ERY 218 54.5 0.25 
B FSA/ analogues  
and SPC 
FSA 2.42 0.3 0.12 0.18 
 SPC 
 
201 12.5 0.06 
       GKFA17 8.30 2.08 0.25 0.31 
 SPC 201 12.56 0.06 
       GKFA37 2.43 0.30 0.12 0.37 
 SPC 101 25.25 0.25 
       GKFA51 4.62 1.16 0.25 0.50 
 SPC 201 50.25 0.25 
       GKFA61 27.73 6.93 0.25 0.50 
 SPC 201 50.25 0.25 
       C FSA/ analogues  
and CLR 
FSA 1.21 0.31 0.26 0.52 
 CLR 0.3 0.08 0.26 
       GKFA17 4.25 2.12 0.50 0.57 
 CLR 0.15 0.04 0.27 
       GKFA37 2.50 1.25 0.50 0.63 
 CLR 0.30 0.04 0.13 
       GKFA51 2.31 0.58 0.25 0.78 
 
 
 
 
 CLR 0.15 0.08 0.53 
 GKFA61 13.87 3.47 0.25 0.52 
 CLR 0.15 0.04 0.27 
 
 
 
 
    D FSA/analogues and 
RIF 
FSA 2.42 0.61 0.25 0.55 
 RIF 0.01 0.003 0.30 
         GKFA17 4.16 2.08 0.50 0.62 
 RIF 0.005 0.0006 0.12 
       GKFA37 1.21 0.61 0.50 0.70 
 RIF 0.005 0.001 0.20 
       GKFA51 2.31 1.16 0.50 0.70 
 RIF 0.005 0.001 0.20 
      
 GKFA61 
 
 
13.87 1.73 0.13 0.63 
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3.1  
FICFSA/analogues 
 
 
 
 
 
 
 
 
 
 
 
3.2.2. Synergy and ability to restore susceptibility to drug-resistant isolates 
On the basis of the synergy displayed by FSA and/or its analogues with SPC (Table 3.1), a 
comparative evaluation was performed on wild-type M. tuberculosis and two resistant strains: 
FSA-R, which is resistant to FSA, and SPC-R, which is resistant to SPC. The SPC-R resistant 
mutants in rrs gene, G1379T, generated in the presence of 5X MIC99 SPC showed > 64 fold 
increase in MIC99 (Kigondu, 2015), whereas the FSA-R mutants were obtained as already 
mentioned (Chapter 2 section 2.2.4). 
Here, the potential to counter pre-existing drug resistance using strongly synergistic 
combinations was examined. The interaction between SPC and FSA (Figure 3-3A), with 
FICI value = 0.15, displayed a higher inhibitory activity against both the FSA-R and SPC-R  
 
Figure 3-2 Interaction assay on 96-well plates. Interactions between FSA and its 
analogues when  combined with (A) ERY, (B) SPC, (C) CLR, (D) RIF against wild–type M. 
tuberculosis H37Rv. Data are representative of two biological replicates.                     
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strains. On the other hand, the interaction between SPC and GKFA51 (FICI value = 0.5), and 
SPC and GKFA61 (FICI = 0.5) (Figure 3-2C & D) was less inhibitory. 
Figure 3-4 shows the correlation between the FICI values determined against wild-type M. 
tuberculosis, and the inhibitory effects of the respective combinations against the 
corresponding FSA-R and SPC-R mutants. A SPC derivative, 1599, which has been reported 
to  overcome native drug efflux
 
was also evaluated
Figure 3-3 Compairing potency in WT strain vs inhibition in mutants. Two-drug interactions between 
FSA its analogues GKFA17, GKFA51, GKFA61 in combination with sub-inhibitory concentrations of SPC 
against wild–type, FSA-R and SPC-R  mutants. *FICI values indicated are data obtained in experiment 
discussed (section 3.2.1, Table 3.1) Data are representative of two biological replicates. 
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Figure 3-4 Compairing potency in WT strain vs inhibition in mutants. Correlation between 
potency (FICI values) versus activity (% Inhibition) of FSA and its analogues GKFA17, GKFA51, 
GKFA61 in combination with sub-inhibitory concentration of (SPC). Assay performed on 
checkerboard using H37Rv wild–type, and resistant mutants, FSA –R; r2=0.679 and SPC-R ; r2 = 
0.947 respectively. 
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When the subinhibitory MIC90 of 1599 was combined with FSA and its analogues, the values 
0.5 > FICI < 4 were obtained, which suggested no interactions (Table 3.2).  
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Table 3-2 In vitro interaction of fusidic acid (FSA), its analogues GKFA17, GKFA37, 
GKFA51, GKFA61 vs a spectinamide, 1599, against M. tuberculosis, H37Rv strain. 
Interaction is interpreted as synergy FICI ≤ 0.5; no interaction 0.5< FICI ≤ 4; antagonistic > 4 
Data are representative of two biological replicates. 
 
Furthermore, these combinations did not display any significant inhibitory effect against the 
FSA-R mutant, (Figure 3-5). The apparent efficacy displayed by these FSA derivatives 
against the FSA-R mutant in the combination (Figure 3-5) was attributed to their disparate 
activities when tested individually (Appendix 2). 
 
 
   Drug combination Compound MIC90 
(µM)individ
ual 
MIC90 
(µM)combi
ned 
FIC FICI 
 Fusidic acid/ 
analogues and 1599 
FSA 
1599 
2.40 0.61 0.25 
0.75  1.04 0.52 0.50 
       GKFA17 33 8.30 0.25 
0.75  1599 1.04 0.52 0.50 
       GKFA37 0.52 0.07 0.13 
0.63  1599 1.04 0.52 0.50 
       GKFA51 5.26 2.63 0.50 
1.00  1599 1.04 0.52 0.50 
      
 GKFA61 14 7.0 0.50 1.00 
 
 
 
 1599 1.04 0.52 0.50 
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3.2.3. Potential use of synergistic combinations to overcome drug resistance in 
standard TB treatment regimens. 
In order to investigate synergy as an approach to overcoming drug resistance, SPC was 
selected for use in this drug combination study because (i) it exhibited potent synergistic 
interactions with FSA and its selected analogues, and (ii) greater inhibitory effects were 
elicited by the potent interactions consisting of SPC against the drug resistant mutants, FSA-
R and SPC-R, of M. tuberculosis. SPC was therefore included for a further combination study 
with RIF and INH, the two frontline drugs that form the backbone of TB treatment. RIF and 
INH were titrated using checkerboard titration in 96-well microtiter plates with decreasing 
sub-inhibitory concentrations of SPC added as an overlay into the individual plates (½X, ¼X, 
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Figure 3-5 Compairing potency in WT strain vs inhibition in mutants.  Two-drug interaction 
between FSA and its analogues GKFA17, GKFA51, GKFA61 in combination with the spectinamide, 
1599 using wild–type H37Rv and the resistant strain, FSA-R . 
 *FICI values indicated are data obtained in experiment shown (Table 3.2) Data are representative 
of two biological replicates. 
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1/8X. 1/16X MIC) as illustrated (Figure 6-2) experimental chapter 6 . The result of the 
experiment performed against the susceptible M. tuberculosis (Figure 3-6A) suggests 
synergy with both ¼ X and ½ X MICs of SPC. This finding from the checkerboard assay was 
further confirmed with time-kill kinetics (Figure 3-6B). The time-kill assay showed that the 
addition of SPC to the RIF-INH combination maintained a constant viable bacterial 
population over 14 days after inoculation.  
 
Figure 3-6 Three-drug in vitro assay Interaction between RIF, INH and SPC against M. tuberculosis (A) 
Checkerboard experiment on five 96-well microtitre plates at SPC concentrations of ½ , ¼ , 1/8, 1/16, 
and 0X MICs. (B) Time-kill assay of drug combination consisting of RIF, INH and SPC at ½ x MICs.  Data 
are from the representative experiment  performed in triplicate. 
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The multidrug drug transporter Rv1258c has been associated with intrinsic resistance to 
SPC.
2 
To explore the influence of Rv1258c in the RIF-INH plus SPC interaction, the three 
drugs were tested against a deletion mutant, Δ1258c (Figure 3-7). No significant change in 
susceptibility was observed with this mutant compared to the wild-type strain. This suggests 
that a different mechanism may be responsible for the synergistic interaction displayed by the 
RIF-INH plus SPC combination. Since M. tuberculosis survives and replicates in 
macrophages using different mechanisms, the synergy of the RIF-INH plus SPC combination 
was evaluated against intracellular bacilli in M. tuberculosis-infected THP-1 cells. The three-
drug combination, RIF-INH and SPC, showed inhibitory activity at 1X concentration (Figure 
3-8). No inhibition was observed when similar concentrations of each drug were applied 
individually. Likewise, no inhibition was exhibited with the RIF-INH combination. These 
key observations may require validation with other experiments such as CFU enumeration.
Figure 3-7 Interaction of RIF, INH and SPC against a knock-out H37Rv mutant. Checkerboard 
experiment at SPC concentrations of ½ X, and 1/8 X MIC against wild-type M. tuberculosis and 
Δ1258c deletion mutant. Data are from the representative experiment  performed in biological 
duplicate. 
 
   78 
 
 
Figure 3-8 Intracellular activity of RIF, INH and SPC combination using THP-1 cells. M. tuberculosis H37Rv ::gfp at a  multiplicity of 
infection (MOI), cells:bacilli 1:10 were subjected to several concentrations  of test drugs (1X and 5X MICs) . Plots detail the inhibitory activity of 
the drugs as determined by fluorescence intensity. Data are from the representative experiment  performed in technical duplicate. 
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On the basis of the potency observed with the three-drug combination in both in vitro and ex 
vivo experiments, the ability of this synergistic combination to overcome genetic resistance to 
one of the combination partner drugs was explored. A RIF-resistant mutant with the genetic 
mutation S531L encoded on the rpoB ß-clamp subunit was used for this investigation. 
Duplicate checkerboard experiments showed that, upon the addition of ½X MIC SPC to the 
RIF–INH plate, the drugs exhibited synergy against the rpoB mutant (FICI  ≤ 0.5) (Figure 3-
9).  
  
 
 
 
Figure 3-9 Activity against pre-MDR M. tuberculosis . (A) Resazurin assay against M. 
tuberculosis rpoB mutant with drug combination RIF-INH-(0X MIC )SPC ; RIF-INH-(1/4X 
MIC) SPC and RIF-INH-(1/2X MIC )SPC (B) Isobolograms showing RIF-INH-(0X MIC)SPC; 
RIF-INH-(1/4X MIC) SPC and RIF-INH-(1/2X MIC )SPC 
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3.3. Discussion 
Bacterial evolution makes it difficult and conceivably impossible to overcome antibiotic 
resistance (Wright, 2016). However, different approaches can be used to circumvent and 
achieve efficacy in the presence of a resistant bacterium. Combination therapies offer one 
method. In a previous study, Chen et al. demonstrated a synergistic interaction between 
SQ109 and RIF when tested against RIF
R
 isolates: at 0.5X MIC, SQ109 was able to increase 
RIF’s activity against de facto resistant organisms in a dose-dependent manner (Chen et al., 
2006). Recently, Yang et al reported the enhanced efficacy of a imipenem-colistin 
combination against multiple drug-resistant Enterobacter cloacae using both in vitro activity 
and a Galleria mellonela model (Yang et al., 2016). Despite the above mentioned efforts, 
very few studies have been undertaken to illustrate the association between the degree of 
synergy and the ability of the particular drug combination to overcome pre-existing genetic 
resistance. In a clinical study, Ankomah et al. suggested that drugs acting synergistically can 
prevent treatment failure even when bacteria resistant to one of the drugs are present at the 
beginning of therapy (Ankomah, Johnson & Levin, 2013).  
 In the first part of this study, the checkerboard assay was used to investigate 
synergistic interactions between FSA and selected analogues in combination with ERY, SPC, 
CLR and RIF. The notable synergy displayed with ERY and not other macrolides such as 
CLR may suggest a specific ERY-FSA interaction which may not exist with other 
macrolides. Synergy was also evident between FSA/analogues and SPC. The conventional 
wisdom, “hitting it hard” for the best outcome, was used to demonstrate that the more potent 
acting synergistically antibiotics are effective at overcoming pre-existing drug resistance 
emanating from either of the combined partners. As shown in this study, the combination of 
FSA and SPC resulted in greater potency, that is, a low FICI value, against drug susceptible 
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bacteria compared to the interaction between its analogues and SPC. Notably, the same FSA-
SPC combination exerted a greater inhibitory effect against the FSA-R and SPC-R mutants. 
There is no definitive explanation for this finding at the present moment. However, it is likely 
that the sustained drug pressure emanating from potent synergistic interactions results in an 
increased effective dose of the drug combination. In addition, some studies have suggested 
that the drug susceptibility of pathogens is significantly enhanced as a result of a reduced 
efflux pump efficiency either by genetic manipulation (Lomovskaya et al., 1999) or addition 
of efflux pump inhibitors (Markham & Neyfakh, 1996; Markham, 1999). The clinical 
relevance of this finding is that, despite the existence of bacterial resistance against a 
combination partner, it would still be possible to achieve optimal therapeutic outcomes with 
the use of appropriate potent drug combinations.  
The second part of this study was aimed at developing a novel combination(s) in a 
three-drug assay. Previous studies have demonstrated the potential of having three-drug 
combinations when compared to individual or two-drug regimens. Recently, Tekin et al. 
reported that combinations of three different antibiotics can often overcome bacteria 
resistance to antibiotics, even when none of the three antibiotics on their own — or even two 
of the three together — is effective (Tekin et al., 2016). In addition, based on the drug 
interaction studies, Ramon-Garcia et al. hypothesized that the synergistic activity of the 
triplet combination might have multiplicative effects (Ramon-Garcia et al., 2011). SPC, a 
drug that exhibited potent interaction with FSA (Table 2.1), was used in this study. Here, 
SPC was deployed as part of a three-drug regimen which also included RIF and INH;- the 
two drugs that form the cornerstone of TB treatment. Previous studies have shown the 
interaction between RIF and INH against M. tuberculosis to have a no interaction effect 
(Bhusal, Shiohira & Yamane, 2005). The inclusion of SPC in this drug regimen was 
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underpinned by studies elsewhere, which reported that 24 out of 70 random combinations 
tested were synergistically active in M. smegmatis (Ramon-Garcia et al., 2011). This suggests 
a large unexplored pool of synergistic combinations. Besides, SPC exhibited synergy with 
several compounds both in vitro and ex vivo (Ramon-Garcia et al., 2011). However, SPC is 
not active against M. tuberculosis when administered individually (Lee et al., 2014). 
In the three-drug combination assay, synergy resulted when sub-inhibitory 
concentrations (½ and ¼X MICs) of SPC were titrated into media containing RIF and INH 
(Figure 3-5A). This finding correlated well with the results of time-kill kinetics (Figure 3-
5B). The time-kill assay suggested, however, that the inhibitory effect of this three-drug 
interaction was bacteriostatic ( 0≥ log10 CFU <3 reduction) and not bactericidal. This 
observation supports previous work which noted that, if bactericidal drugs are most potent 
with actively dividing cells, then the inhibition of growth induced by a bacteriostatic drug 
may result in an overall static effect when the drug is used in combination with a bactericidal 
drug (Ocampo et al., 2014). However, the resulting synergistic interaction achieves a more 
efficient clearance at lower concentrations.  
Towards elucidating the mechanism of action for this synergistic interaction, a 
knockout mutant was used which was deficient in major superfamily multidrug exporter 
protein, Rv1258c. This protein has been shown to be responsible for intrinsic SPC resistance 
(Lehár et al., 2009). The interaction of RIF-INH plus SPC using the Rv1258c-deficient 
mutant did not reveal significant hyper susceptibility, implying that the evident synergy may 
be as a result of a different antibiotic target interaction.  
In attempting to exploit synergy for potential optimal treatment outcomes, an 
investigation of the RIF-INH plus SPC interaction was performed in a RIF-resistant mutant. 
The rpoB resistant strain had an MIC value > 50 times the MIC for the drug susceptible M. 
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tuberculosis. Figure 3-9 shows that the addition of ½ and ¼X MICs of SPC also facilitated 
inhibition of the drug resistant M. tuberculosis strain. As with the drug susceptible H37Rv 
strain, a clear explanation for the synergy between RIF-INH plus SPC combination against 
the rpoB mutant is presently lacking. INH targets mycobacterial cell wall synthesis, 
presumably allowing more SPC to get into the bacteria. However, access alone may not 
necessarily contribute to the synergistic interaction. Chen et al. reported synergy between 
SQ109, a presumed cell wall synthesis inhibitor, and RIF. On the other hand EMB, which 
also affects mycobacterial cell wall synthesis, did not exhibit synergy with RIF (Torella, 
Chait & Kishony, 2010). 
Studies have shown RIF to be an efficient inducer of cytochrome P450 (CYP 450), a 
superfamily of haem-containing enzymes involved in the biosynthesis of compounds such as 
sterols, steroids, and fatty acids as well as detoxification of xenobiotics and chemicals 
(Sarathy et al., 2016).
 
 RIF has been linked with the induction of CYP both in humans and in 
M. tuberculosis (Zhang et al., 2007). The elevated levels of CYP has been associated with 
drug resistance due to the enhanced rate of elimination of the drugs by  metabolism and 
detoxification pathways. INH, on the other hand inhibits CYP in M. tuberculosis (Zhang et 
al., 2007). The ability of INH to inhibit CYP in M. tuberculosis may contribute to synergy in 
the RIF-INH plus SPC combination when the active form of INH is not rapidly eliminated  
inside M. tuberculosis  and at the same time, the drugs act on multiple targets. 
There are prospects of combining SPC with RIF-INH . SPC, given by intramuscular 
injection to achieve therapeutic concentrations in serum of about 100 mg/L 1 h after a single 
2-g dose, a ≥4-fold increase in its effectiveness within the triple combination would 
potentially allow for oral formulation. This is critical, especially in treating TB out-patients. 
In summary, these in vitro and ex vivo results suggests that the RIF-INH plus triple-
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combination, may be an effective therapeutic option for the treatment of both the drug 
susceptible and resistant M. tuberculosis infections. In overall, these investigations suggest 
that synergy can be exploited to potentially improve treatment. 
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Chapter 4          
Delineating bactericidal versus bacteriostatic agents 
4.1. Background 
 Despite the achievements realized with whole-cell (WCS) assays that have yielded numerous 
hit compounds against TB, the development and validation of methods for rapidly selecting 
bactericidal compounds still remains a challenge. Approaches such as Microplate Alamar 
Blue (MABA) and the Resazurin-based Microplate Assay (REMA) merely provide MIC 
information and do not predict the cidality of the test compounds. Moreover, the reporter 
genes such as luciferase (lux) or gfp require modifications for each strain (Primm & 
Franzblau, 2007). So far, the conventional gold standard method of delineating bactericidal 
compounds involves plating of bacilli following drug exposure and enumerating the colony 
forming units (CFUs) after 3-4 weeks. This is labour intensive, difficult to automate and 
slow, and so is not easy to adopt for hit prioritization of small molecules emanating from 
HTS cascade.  
The main aim of chapter 4 was to develop simple, rapid and robust assays that would 
act as preliminary screening tool(s) to enable the initial assessment and determination of 
bactericidal compounds. Such understanding would aid in the prioritization of hits for the 
progression into drug discovery programmes. In addition, this chapter explored 
methodologies that allow for a fast and reliable monitoring of mycobacterial physiological 
state as well as cell growth, particularly within the context of new TB drug discovery.  
A modified “spot-assay” technique, reported by Kaur et al.  was employed to rapidly 
delineate bactericidal and bacteriostatic drugs, Chapter 4 section 4.2.2 (Kaur et al., 2015). 
The modified spot-assay method relied on establishing a correlation by a visual comparison 
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of the bacterial outgrowth in the 24-well agar plate containing the test agents (4X, 2X, 1X 
and ½X MIC) with the wells having the reference bactericidal/static agents. The 
determination of MIC90 formed the starting point for the spot-assay on a 96-well plate, 
(Appendix 3). The fast-growing surrogate M. smegmatis mc
2
155::gfp was used to enable 
rapid assessment of the drugs susceptibility profiles. Plating was subsequently carried out on 
a 24-well plate upon antibiotic treatment at 4X, 2X, 1X and ½X MICs and compared with 
that of the reference drugs. The absence or very few colonies at concentrations ≥ 1X MIC 
implied bactericidal effect of the test agents; also exhibited by the reference drug, DCS. On 
the other hand, bacteriostatic agents displayed the presence of bacterial colonies at 1X MIC 
or possibly higher concentrations. This modified approach has the advantage of offering a 
simple, economical and qualitative HTS with the potential to impact on the TB drug 
discovery process. 
 In addition to the spot assay, section 4.2.3 of this chapter illustrated the work 
employed through the use of flow cytometry (FCM) and the fluorescent microscopy 
techniques for rapid assessment of mycobacterial physiological state as well as the growth 
inhibitory effect of antibiotic drugs against M. smegmatis, a fast growing surrogate. This is 
key, considering the slow growth of M. tuberculosis, coupled with the challenges of working 
with a human pathogen under biological safety level 3 conditions. This has contributed to 
difficulty of gaining insight into the organism’s physiology and metabolism (Warner, 2014). 
The fluorescent techniques and other optical detector methods are opted for, to provide a 
rapid and real-time assessment of bacterial viability upon antibiotic treatment. 
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4.2. Results 
4.2.1. Bactericidal/static evaluation of antibiotic drugs using the spot assay technique 
The MICs of the selected drugs were determined against M. smegmatis and are listed in 
Table 4.1 
Table 4-1 MIC90 of the selected test drugs against M. smegmatis 
Compound Abbreviation MIC90 (µM) 
 
Capreomycin CAP 0.8 
Ethambutol EMB 1.0 
Bedaquiline BDQ 0.2 
Isoniazid INH 13.0 
Spectinomycin SPC 50.0 
Rifampicin RIF 10.0 
Erythromycin ERY 8.0 
Streptomycin STR 0.5 
Hygromycin HYG 4.1 
Fusidic acid FSA 80.8 
D-cycloserine DCS 75.0 
 
A time-curve assay was used to determine the bactericidal-static activity of FSA against M. 
smegmatis (Figure 4.1). At MIC90 of 80.8 µM, FSA exhibited bacteriostatic activity over the 
24 h period. Information on the bactericidal activity of DCS against M. smegmatis was 
obtained from previously reported studies (Feng & Barletta, 2003; Peteroy et al., 2000). 
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Figure 4-1 Bacteriostatic effect of FSA at MIC90 of 80.8 µM. Time-kill experiments for M. 
smegmatis following exposure to FSA concentrations 0, 40.4, 80.8, 162.6, 400.4 and 800.8 
µM. Viable cell concentrations were determined by plating on Middlebrook 7H10 agar. Data 
are from the representative experiment  performed in technical duplicate. 
 
FSA and DCS, the two selected drugs, showed distinct patterns in the observed colony 
forming units (Figure 4-2). Using FSA, a fairly dense population was observed on the culture 
medium of the 24-well plate that consisted of 1X MIC drug. A similar population density was 
seen with the 2X MIC population, an indication of the bacteriostatic tendency of the drug. 
DCS, on the other hand showed remarkably few colonies at 1X MIC and no CFU were 
observed at 2X MIC presumably because of its bactericidal effect. CAP and ERY exhibited 
dense mycobacterial populations at the 1X MICs respectively, suggesting bacteriostatic 
effects. HYG, STR, RIF, EMB and SPC manifested bactericidal activity whereas BDQ 
yielded an intermediate profile which was difficult to define unequivocally.  
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These preliminary findings were compared with the reported data from previous studies on 
M. smegmatis (Table 4.2). 
Table 4-2  Comparison of bacteriostatic/bactericidal activity inferred from the spot assay 
with the reported data 
Compound Abbre
v. 
Experimental 
inference 
 
Reported in 
M.smegmatis 
Method used Reference 
Capreomycin CAP Static Cidal Time-kill Lin et al., 2014 
Ethambutol EMB Cidal Static Enzyme 
inhibition 
Forbes et al., 2015 
Bedaquiline BDQ Not clear Cidal Oxygen 
consumption 
rate 
Hards et al., 2015 
Isoniazid INH Cidal Cidal Time-kill da Silva etal.,, 2009 
Spectinomycin SPC Cidal Static Spot-assay Kaur et al., 2015 
Rifampicin RIF Cidal Cidal Oxidation 
and binding 
Staudinger et, 2014 
Erythromycin ERY Static Static MBC/MIC 
assay 
Pankey & Sabath, 2004 
Streptomycin STR Cidal Cidal MBC/MIC 
assay 
Heifets & Lindholm-Levy, 1989 
Hygromycin HYG Cidal Cidal Enzyme 
inhibition 
Rosen & Mobashery, 2012 
A B 
Figure 4-2 Bactericidal versus static effects: 24-well plate spot-assay of selected drugs at 4X, 
2X, X and ½X MIC 14 days post incubation. FSA and DCS used as reference for bacteriostatic 
and bactericidal drugs respectively. CFUs on wells containing the test agents (CAP, EMB, BDQ, 
INH, SPC, RIF, ERY, STR and HYG) are visually compared with those of reference drugs at 
their respective concentrations. X- indicates 1 x MIC90 wells for SPC and ERY.  
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4.2.1 Profiling bacillary populations in log and stationary phases. 
FSA and SPC were selected as antibiotic agents owing to their potential for further 
development as a combination therapy on the basis of the synergy described above (Chapter 
2). M. smegmatis was adopted as proxy for M. tuberculosis in developing the assays. Calcein-
AM (CA-AM) was used a marker for viable cell; retention of CA-AM by the cells indicate 
enzyme activity as well as membrane integrity. Propidium iodide (PI) was used a marker for 
non-viable (membrane-compromised) cells, because it is excluded by intact plasma 
membranes
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Figure 4-3 FCM dot plots of M. smegmatis  (A) unstained at OD600
 0.5, and stained with PI at OD600 of (B) 0.5 (C) 1.0 (D) 2.0 (E) 3.5 (F) Heat-killed 
cells. Data are representative from experiments performed in biological duplicate. 
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In order to assess membrane integrity in both actively replicating and stationary phase bacilli, 
single-staining by propidium iodide (PI) was utilized. The staining profiles observed during 
the two phases of growth are shown in Figure 4-3. Distinct fluorescence was observed 
between the stained and unstained cell populations. As the culture progressed from 
exponential phase to stationary phase, the PI fluorescence intensity measured on the FL3 
detector increased, perhaps indicating the presence of more permeabilized cells owing to cell 
death or injury. At an OD600 of 0.5, indicative of mid-exponential growth phase, less PI 
fluorescence intensity was observed than at higher OD values - that is, at OD600 readings of 
1.0, 2.0 and 3.5. In addition, a more compact or homogenous population was evident in the 
stationary phase culture (OD600 of 2.0 and 3.5), which contrasted with the heterogeneity 
evident in the log phase culture. The inverse profile was observed using the CA-AM stain 
(Figure 4-4).
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Unstained OD = 0.5 OD =1.0 
OD =1.4 OD =3.5 
B C A 
D 
E 
Figure 4-4 FCM dot plots of M. smegmatis  (A) unstained at OD600
 0.5, and stained with CA-AM at OD600 of (B) 0.5 (C) 1.0 (D) 1.4 (E) 3.5. Data 
are representative from experiments performed in biological duplicate. 
 
 
 
   95 
 
 
Higher CA-AM fluorescence was observed with log-phase cultures (OD 0.5, 1.0 and 1.4) 
compared to stationary phase (OD 3.5). That is, the proportion of PI and CA-AM stained 
populations correlated negatively. For both PI and CA-AM stained cells, the stationary phase 
population (OD600 2.0 or 3.5) profiled by the forward-scatter height (FSC-H), exhibited a 
shift towards the left relative to the sub-population of the exponentially growing culture, 
OD600 0.5, (Figure 4-5). 
 
 
 
 
 
 
 
FSC-H provides a measure of the distribution of cell sizes; therefore, the pattern observed 
reinforced the interpretation that stationary phase cells are smaller and more homogenous.  
To further explore the two sub-populations, P1 and P2, these gated cells were sorted 
and some sample slides examined under bright-field and fluorescent microscopy for evidence 
of the differential aggregation. Slides mounted with the P1 sub-population revealed 
aggregated cells, a triplet and single cells. On the other hand, P2 sub-population displayed 
mainly doublet and single cells (Figure 4-6) which might suggest differential composition in 
P1 and P2 sub-populations.  
 
CA-AM  stained 
OD 3.5  
OD 0.5 
OD 3.5 
OD 0.5 
PI stained A B 
Figure 4-5 FCM histogram overlays of M. smegmatis FSC-height (A) PI (B) CA-AM stained at 
log phase OD600 0.5 and stationary phase OD600 3.5  
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4.2.2 Impact of the selected antibiotics on M. smegmatis viability and cell damage. 
FCM was used to evaluate the viability of M. smegmatis after incubation with various 
concentrations of FSA and SPC. The cells were stained with CA-AM. “Viable cells” were 
defined as those that were able to reproduce; their reproductive capacity requires both 
metabolic activity and membrane integrity.(Nebe-von-Caron et al., 2000). The MIC90 values 
of the test drugs were determined using the conventional approach against an M. smegmatis 
gfp mutant. 
 
Exposure to FSA  
The respective histograms of the untreated M. smegmatis populations; the unstained cells 
used as a negative control, CA-AM stained at 0 h and CA-AM stained after a 72 h incubation 
are shown, (Figure 4-7).
A C D B 
P1 sub-population P2 sub-population 
Figure 4-6 Representative microscopic images in bright-field (A-C) and fluorescent 
microscopy (D) showing M. smegmatis after cell-sorting of the two sub-populations; P1 and 
P2. (A) aggregated cells (B) a singlet and triplet (C) singlets and a doublet (D) singlets 
bacteria . Selected slides from P1 sub-population manifested aggregated cells, triplets and 
singlets. On the other hand, viewed slides with P2 sub-population  displayed mainly 
doublets and singlets with notable absence of aggregated cells and triplets.  Data are 
representative of three biological replicate. 
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 CA-AM fluorescence (72 h) CA-AM fluorescence (0 h) unstained 
B C A 
  Bisector 
line 
Figure 4-7 Fluorescence histograms of M. smegmatis showing untreated culture controls CA-AM (–ve) and CA-AM (+ve) on the left and right hand-side of 
the bisector line respectively.  (A) unstained cells (B) stained with CA-AM 1µM for 60 min at the start of the experiment (0 h) , (C) stained with CA-AM 
1µM for 60 min after 72 h of incubation. Data are representative of experiments performed in duplicate. 
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M. smegmatis cells were treated with FSA at ½X, 1X and 5X MIC and incubated over a 72 h 
time-course, Figure 4-8. The CA-AM stained cells were analysed at various time-points 
throughout the time-period. At a concentration of ½X MIC of FSA, the population of CA-
AM stained positive cells remained above 98% over the 72 h period, similar to the untreated 
population . In contrast, the number of bacilli which returned a positive CA-AM signal with 
FSA treatment at 1X MIC was reduced by about 54% in 72 h. At an FSA concentration of 5X 
MIC, a more significant inhibitory effect was observed; the CA-AM stained population 
reduced to 0.01% at the 72 h time period. However, earlier time-points - that is, 24 and 48 
treatment with 5X MIC - did not reveal any notable difference compared to the effect 
observed  with  1X  MIC.  
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 Figure 4-8 Fluorescence histograms of M. smegmatis treated with FSA at 24, 48 and 72 h. CA-AM (–ve) and CA-AM (+ve) on the left and right 
hand-side of the bisector line respectively. 
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Exposure to SPC 
SPC showed the greatest inhibitory effect at ½X MIC during the 24, 48 and 72 h period in 
contrast to that of ½X MIC FSA (Figure 4-9) over the same time period. However, the 
treatment with 1X MIC SPC showed similar histograms with that of ½X MIC since the CA-
AM positive cells were maintained at about 80% in both cases. Furthermore, treatment with 
5X MIC SPC manifested in greater than 90% inhibition at the 72 h time-point, evident by a 
Calcein –ve population of 93.3% (Figure 4-9, bottom-right panel). In stark contrast to the 
FSA activity, the area under curve for the CA-AM negative histogram of 5X MIC SPC was 
observed to be much smaller at the 72 h time-point. This implied a significant reduction in 
the overall bacterial population― possibly  a result of  cell lysis. 
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Figure 4-9 Fluorescence histograms of M. smegmatis treated with SPC at 24, 48 and 72 h. CA-AM (–ve) and CA-AM (+ve) on the left and right hand-
side of the bisector line respectively. >90% inhibition, that is, the bacterial population with Calcein –ve  = 93.3% is exhibited at 72 h of 5 X MIC. In 
addition, the area under the curve in this panel is much smaller compared to the rest of the panels. 
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4.3. Discussion 
The spot assay strategy for selecting bactericidal agents highlighted a preliminary study, 
based on a comparative visualization of the test agents with the reference drugs. Compounds 
emanating from a large HTS screening cascade could potentially be delineated into cidal or 
static compounds. This would then allow hits’ prioritization into the drug discovery 
programmes.  
This assay demonstrated a straight-forward technique that can be used to qualitatively 
display the extent at which a compound manifests cidality. Based on a simple two-step 
procedure; (i) MIC determination on a 96-well plate and (ii) spot-assay method on a 24-well 
agar plate, the assay exhibited some consonance between the experimental outcome and the 
conventional assays for bactericidal determinations. However, this assay did not suggest any 
reduction of the incubation time. The other down-side was that the assay could not provide 
unequivocal proof of the cidal activity of the compounds. For example, the activity of BDQ, 
could not be determined clearly since it was considered to lie within the ‘grey’ area. Further 
wash-out experiments may be required at a later stage in the development for the most 
promising compounds. 
Hendon-Dunn et al reported the use of FCM to assess the response of M. tuberculosis  
to antibiotics with different modes of action (Hendon-Dunn et al., 2016).  By utilizing RIF 
and INH, the study  illustrated a method for rapid analysis of drugs’ susceptibility. Besides, it 
provided information about the drugs’ potential mode of action; antibiotics targeting the cell 
wall gave a  distinctive fluorescence profile compared to those inhibiting intracellular 
processes (Hendon-Dunn et al., 2016).  For example, the inhibitory effect on the bacterial 
population with the cell wall targeting antibiotics, INH and BTZ-043, displayed an early and 
steep rise in SYTOX-green (SG) staining; a marker which  permeates through  damaged 
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bacteria and binds to DNA (Roth et al., 1997). On the other hand, a steady rise in the SG-
stained population was observed for rifampicin exposure as well as other intracellular-
targeting antibiotics.  In order to further assess the robustness and utility of FCM, sections 
4.2.2 and 4.2.3 of this chapter described the results of the FCM and the fluorescent 
microscopy techniques applied for a quick assessment of mycobacterial physiological state 
and their susceptibility to antibiotics. Differences in physiological state of M. tuberculosis 
can be critical for its survival. For example, M. tuberculosis can persist for many years within 
the tissues of the host’s lung without causing clinical disease (Orme, 1988). Evidence has 
suggested that cells survive in nutrient-deprived stationary phase. As a follow-up to this, 
Smeulders et al. studied the stationary-phase survival of M. smegmatis, as model for 
mycobacterial persistence (Smeulders et al., 1999).
 
Emanating from their studies, a transition 
from late log phase into early stationary phase was associated with the cell’s ability to sense 
the depletion of glycerol and initiate a shut down into stationary phase. This involved, uptake 
of the remaining glycerol from the medium, cells displayed a reductive cell division, 
resistance to both osmotic and acid stress and pool mRNA stabilized. Studies conducted with 
gram-negative species such as Escherichia coli, Vibrio sp., and Salmonella typhimurium 
indicated a decrease in cell size, increased stress resistance, increases in RNA stability, and 
major changes in protein synthesis as some of the morphological and physiological changes 
that occur.  
Here, analysis with the flow cytometer revealed the physiological heterogeneity 
within the exponential and stationary phase populations. For example, cultures from the 
exponential phase of M. smegmatis; unstained, and CA-AM stained at OD600 0.5, 1.0 and 1.4, 
displayed two sub populations, P1 and P2, (Figure 4-4). These subpopulations mainly 
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consisted of viable cells as indicated with high fluorescence upon staining with CA-AM - a 
marker for cell viability owing to esterase activity (Díaz et al., 2010). 
Moreover, low fluorescence was observed with PI staining (Figure 4-5). The transition of M. 
smegmatis cell population from log phase to stationary phase was also accompanied with a 
cell size reduction. This may possibly be explained by the rearrangement in peptidoglycan in 
cell wall of the stationary phase bacteria leading to size reduction (Oliver, 2010). The 
rearrangement in peptidoglycan can be triggered by various factors: Faghri et al reported a 
change from bacilli to coccoid in Helicobacter pylori on exposure for three days to sub MIC 
antibiotics (Faghri et al., 2014). Yet in another study, Besnard et al. reported morphologic 
changes following nutrient starvation in Campylobacter jejuni (Besnard, Federighi & 
Cappelier, 2000).
 
 Recent work by Wui et al on M. smegmatis revealed the development of 
small – cell survival morphotype  when the bacteria were exposed to mild starvation 
conditions (Wu, Gengenbacher & Dick, 2016). Using fluorescence microscopic analyses, 
small resting cell (SMRC) morphotypes progressed through partitioned multi-nucleoided cell 
intermediates, which divide to generate mono-nucleoided SMRCs (Wu, Gengenbacher & 
Dick, 2016). 
This work also revealed that FCM could be applied to improve the understanding of 
antibiotic effect on mycobacteria. In this study, FCM assessment highlighted the succession 
of cell changes that occurred in antibiotic stressed populations of M. smegmatis. Both FSA 
and SPC were less active against M. smegmatis at both ½X and 1X MIC. Even at 5X MIC, 
considerable esterase activity was maintained with both drugs at 24 h and 48 h treatment. 
However, at 72 h, a sharp reduction of more than 90% of the respective populations showed 
cells that lack esterase activity due to injury or death. Moreover, the mean fluorescence 
intensity observed with both ½X and 1X MIC SPC was higher than that displayed with FSA 
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or control cells. Curiously, this increase in fluorescence intensity corresponded with the 
increase in cell count. This may suggest a differential response of the bacteria towards these 
antibiotics that inhibits different stages of the  translation process (Figure 1-7). Alternatively, 
a more permeable cell wall due to the antibiotic treatment may cause leakage of the CA-AM 
thereby resulting in false positives. The apparently limited inhibition observed with both FSA 
and SPC at early time points, 24 h or 48 h, may explain their mechanism of action (Almeida 
Da Silva & Palomino, 2011). Early inhibition, such as 24 h, indicate that the mode of action 
could involve a lesion of the cell membrane resulting from the direct damage of the cell 
membrane while a late inhibition would imply a metabolic impairment leading to secondary 
damage to the cell membrane. A previous study carried out by Moghoofei et al. on 
Pseudomonas aeruginosa, reported that these bacilli could be converted to coccoid form 
under antibiotic stress (Moghoofei et al., 2015). The conversion may lead to resistance to 
antibiotics due to changes in cell wall cross-link or decreased metabolic activity 
(Sachidanandham, Yew‐Hoong Gin & Laa Poh, 2005; .McDougald et al., 1998). Similar 
investigations  can be undertaken with mycobacteria. The application of both spot assay and 
FCM techniques represents powerful tools for rapidly selecting potential lead compounds 
with either bactericidal or bacteriostatic activity; thereby facilitating drug discovery. 
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Chapter 5          
Conclusions and Future Perspectives 
5.1. Conclusions 
Urgent measures are required to sustain an active TB drug pipeline, particularly at the pre-
clinical phase of development. The major goal of this thesis was to develop and apply 
improved methods for advancing novel drug combinations in TB drug discovery. Thus, an 
integrated approach was adopted which encompassed the utilization of different strategies, 
tools and experimental models. These efforts aimed to deliver synergistic drug candidates 
that would allow for rapid translation into clinical trials within the current anti-TB drug 
pipeline. 
 This thesis fits into two broad categories; (i) evaluation of synergistic drug 
combinations and (ii) rapid investigation of the mode of action of experimental compounds 
with demonstrated anti-mycobacterial activity. Chapters 2 and 3 focused on developing and 
exploring synergistic drug interactions with existing anti-TB antibiotics. Furthermore, a drug 
repurposing strategy was employed. In defining synergy, the effect elicited by a combination 
of compounds is greater than that observed from the individual compounds. Consequently, 
this may result in increased therapeutic efficacy, reduced drug concentration required, shorter 
treatment duration, and potentially reduced side-effects (Williamson, 2001). In order to 
identify combinations that display synergistic interactions, a number of techniques were 
developed and optimized with different experimental models. Using M. smegmatis, prior to 
application in M. tuberculosis, allowed the manipulation of various preliminary experiments 
within the BSL2 laboratory.  Furthermore, the faster growth rate of M. smegmatis in 
comparison to M. tuberculosis made it possible to carry out formative studies in a shorter 
period of time, thus minimizing the time-consuming aspect of working with M. tuberculosis 
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at the initial stages. In addition, the use of M. smegmatis allowed insight into potential 
synergistic activity of selected drug combinations that were expected to show good 
concordance; in that, drugs that synergized with FSA using M. smegmatis were similarly 
expected to synergize  with FSA  against M. tuberculosis owing to their genetic relatedness..  
The modified checkerboard combination assay was implemented to uncover potential 
synergies among the interacting agents. In this assay, the efficacies of the single agents and 
the resulting combinations could be determined in a single 96-well plate. This single-plate 
96-well  matrix checkerboard assay can be automated to provide a high-through put screening 
platform that would allow for hundreds of investigational compounds to be combined in 
hundreds of possible pairings and dose variations.  
The standard two-drug combination assays were extended here to include an 
innovative 3-D approach that enabled the simultaneous use of 3 agents. Using the 3-drug 
combination set-up, the in vitro synergistic effect of RIF-INH plus SPC was demonstrated 
against M. tuberculosis wild-type strain. Moreover, by applying this method, it was shown 
that SPC restored the susceptibility of the RIF-R M. tuberculosis rpoB mutant to the RIF-INH 
combination regimen. The exact mode of action underlying the synergy evident in this assay 
remain to be determined; however, this result suggests the possibility of selecting 
combination agents that will retain activity even against genetically resistant mutants.  
The construction of isoboles, i.e. isoeffective curves, applied in the course of this thesis 
allowed analysis and a clear representation of synergistic interactions in both the 2- and 3- 
drug combinations. Although these isobolograms largely demonstrated the drugs’ synergistic 
interactions, their applications are not without limitations. For example, the nature and extent 
of any interaction may be dose-dependent; that is, a combination of two compounds may act 
synergistically within one dose range while showing antagonism within another. By 
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incorporating a large number of data points, it is possible to generate representative 
isobolograms illustrative of the drug combination’s effect at a specific level (Martinez-Irujo 
et al., 1996). 
The potency of TB compounds, as determined by MIC and MBC evaluation, is a key 
consideration in early drug discovery programmes. As pointed out, the second broad aspect 
of this thesis engaged different strategies for rapid delineation of bactericidal activity. Drug 
candidates which exhibited strong synergy including FSA and SPC were prioritized for this 
study, both individually and in selected combinations. In the MIC and MBC evaluation, a 
modified in vitro cell regrowth assay adopted from Zhang et al. demonstrated a simple and 
robust bactericidal activity assay against M. tuberculosis (Zhang et al., 2007). Here, the MIC 
of test compounds was determined within 7 days followed by MBC determination. Previous 
work by Andreu et al. described the determination of all of standard drugs using a Lux 
reporter strain and report that MICs for all the drugs tested can be determined by day 3 
(Andreu et al., 2012). While this may be true for the standard optimized drugs, some 
experimental compounds are not likely to be optimized for their killing properties and may 
need longer exposure time. Therefore, day 7 was seen as optimal time for MIC determination. 
This aberration may be as a result of the physico-chemical properties of different drugs which 
can influence their ability to access the bacteria over a period of time. As a result, 
discrimination between bacteriostatic and bactericidal agents may not be easily ascertained 
over a shorter period of time. In addition to the fact that the regrowth experiment was easy to 
perform, the time taken for the generation of these results (approximately 14 days) was 
shorter compared to the conventional method of CFU enumeration.  
The FCM approach (Chapter 4) was adopted as an efficient alternative due to its 
ability to monitor viability and growth of mycobacterial cells in response to antibiotic 
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treatment rapidly and with high sensitivity. As already highlighted, it allows for the detection 
of viable but non-culturable (VBNC) cells which are not captured by the conventional CFU 
enumeration (Hendon-Dunn et al., 2016). Herein, FCM assay demonstrated the 
morphological heterogeneity, based on size/shape, of populations within the exponential 
growth phase, whereas at a later phase of growth, a more compact homogenous population 
was observed. The population of stationary phase cells was seen at a lower fluorescence of 
the FSC-height with FCM analysis, suggesting a reduced cell size compared to the 
exponential phase population. Bacteriostatic activities of both FSA and SPC against M. 
smegmatis were indicated, however SPC manifested bactericidal tendencies at much higher 
drug concentrations and after prolonged exposure. As mentioned in Chapter 4 (section 4.3), 
both FSA and SPC are translational inhibitors, therefore the FCM profiles may be attributed 
to the delayed response compared to what might be observed with a cell wall inhibitor. 
Moreover, injured cells, as a result of antibiotic exposure, may not recover and could still 
retain some enzymatic activity as shown with CA-AM staining. The use of FCM in this thesis 
for bactericidal analysis may, therefore, be considered as a work in progress at best. While 
FCM permits the detection of the cells without any requirement that they can grow, our 
detection of ‘viability’ was limited to presence of esterase activity determined by CA-AM 
staining. Furthermore, in antibiotic-stress environments, the metabolic activity may be 
decreased below the threshold of detection. Besides, prior determination of an optimal dye 
concentration would be necessary for better resolution. Since CA-AM staining alone may not 
give a definite indication of the cell’s viability, other reporter probes may be useful in the 
validation for viability analysis. 
Besides the application of FCM, a modified qualitative spot assay strategy to 
elucidate bactericidal and bacteriostatic mycobacteria using M. smegmatis displayed a 
remarkable correlation between the observed experimental activities and those reported using 
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standard mode of action determinations.  The spot assay technique is key, particularly in 
preliminary medium-throughput assays for the potential  discrimination of bactericidal agents 
coming out of hits in drug discovery. Moreover, it is a useful tool when working with 
fastidious organisms (Wayne, 2007). However, unlike FCM, the spot assay may not be 
utilized to identify the bacteria that are in a state of very low metabolic activity and do not 
divide, but are alive and can become culturable on resuscitation (Shleeva et al., 2004).   
5.2. Future Perspectives. 
The results obtained from this work underscore the potential to explore compound synergies 
in TB drug discovery by use of the matrix checkerboard assay. However, further 
modifications of checkerboard assay may be adopted. As noted by Hsieh et al., a major 
problem inherent in this is the use of two-fold dilutions for the antibiotic concentrations 
(Hsieh et al., 1993). This exponential increase in dilutions potentially makes this method 
inherently unsuitable for evaluating synergy, thus, requiring newer methods or modifications. 
An approach that utilizes multiple plate set-up at different starting concentrations of the test 
drugs  presents a viable alternative. 
In this work, higher potency with very low drug concentrations was demonstrated 
when FSA interacted synergistically with ERY. This is a key consideration for the efficient 
and rapid elimination of a pathogen. In addition, the ability of more potent drug interactions 
to circumvent pre-existing resistance even to the extent of restoring drug susceptibility was 
demonstrated. The delineation of cidal or static antimicrobial agents has been shown to be 
play a significant role in hit prioritisation. This is mainly reinforced by the fact that the 
successful use of static drugs to treat infections requires an intact host immune system. 
Accordingly, the primary perspective to extend this work will be the in vivo 
evaluation of synergism between FSA with the anti-tubercular drugs and/or other antibiotics 
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such as ERY and SPC, which have displayed synergy in vitro. Secondly, it has been shown 
that potent combinations have the ability to restore drug susceptibility. This is achieved 
where there is intrinsic genetic resistance to one of the combination drugs. Therefore, it will 
be important to prioritize highly potent synergistic combinations for the in vivo drug 
susceptibility testing against a M. tuberculosis H37Rv strain that is resistant to either of the 
drugs within the combination.  
 Thirdly, the predictive model adopted in Chapter 2 indicated the potential of FSA and 
synergizing drugs to penetrate necrotic tuberculosis lesions based on the differential 
partitioning values, clog P. It might be worth investigating the potential of these drugs to 
complement other combination partners in their ability to penetrate caseous granulomas. 
Finally, the overall and greater vision of this work is to contribute to the enormous 
task of eradicating TB through new drug development and the application of innovative 
combination regimens that are rationally designed in the preclinical stages. The general 
course of this thesis is summarized in Figure 5-1.
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Improved methods for advancing novel 
compounds as a combination in TB treatment
Search for synergy
(2D- and 3D- matrix screening
Tools for rapid assessment 
of drug’s MoA
(cidal vs static)
Rationale:
-Improved efficacy at low doses
-Curtail emergence of resistance/ Restore drug 
susceptibility
Rationale:
-Hit prioritization for early drug 
discovery programs
Results:
-FSA/Analogues displayed potent synergy with SPC  and 
ERY (FICI < 0.5).
-High potency between FSA and SPC restored 
susceptibility in a pre-existing resistant strain.
-RIF-INH plus SPC showed in vitro and ex vivo synergistic 
interaction in drug susceptible and rpoB mutant strains
Results:
-Spot assay  exhibited  a general agreement 
with  the conventional assays used for 
bactericidal determination.
-Bactericidal drugs showed static tendencies 
when combined with bacteriostatic drugs. 
-FCM analysis rapidly revealed  bacteriostatic 
activity  of FSA and  bactericidal tendencies of 
SPC at higher concentrations.
Conclusion:
-methodical approach in drug combinations showed greater 
potential to deliver clinical candidates for the treatment of DS- and 
DR-TB.
Figure 5-1 Schematic representation highlighting key aspects in the thesis 
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Chapter 6          
Experimental 
6.1.  Chemicals and reagents  
 Chemicals and solvents were mainly purchased from Sigma-Aldrich.    FSA analogues were 
synthesized in Kelly Chibale’s lab., chemistry department at the University of Cape Town. 
Bedaquiline (BDQ) was purchased from Asclepia MedChem Solutions (Belgium). A 
spectinamide, 1599, was donated by  r. Richard E. Lee, St. Jude Children’s Research 
Hospital & University of Tennessee. 5mM stock concentrations of the drugs were prepared in 
DMSO at -20°C.  Working solutions of the antimicrobial agents were prepared in distilled 
water. 
Table 6-1 Strains and plasmids used in this study 
Strain Description Reference or source 
M. smegmatis   
mc
2
155 Wild-type Laboratory collection 
M. tuberculosis   
H37RvMA Wild-type (Ioerger et al., 2010) 
Macrophages   
THP-1  Undifferentiated monocytes Laboratory collection 
Plasmids   
pMSP12::gfp Rv2390c (Tan et al., 2013)  
 
 
6.2.  Bacterial strains and growth conditions.  
The bacterial strains and plasmids used in this study are detailed in Table 6.1. M. smegmatis 
mc
2
155 experiments were performed in Middlebrook (MB) 7H9 medium enriched with 10% 
Glucose salt (v/v), 0.2% Glycerol and 0.05% (v/v) tween-80 for 3 days at 37 °C. Freezer 
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stocks of M. tuberculosis H37Rv (Ma) and H37Rv.pMSP12::gfp mutant were grown in 
Middlebrook (MB) 7H9 supplemented with 10% oleic acid-albumin-dextrose-catalase 
(OADC) (Difco) at 37  °C for approximately 3 days sub-cultured and grown further to attain 
an OD600 0.5. The cell suspension was then adjusted to give a final concentration of 10
5
 
cells/ml at the time of inoculation. 25 µg of kanamycin per ml was added into the gfp mutant 
each time a culture was started. 
 
6.3. Drug susceptibility testing.  
The MICs for the selected drugs were determined by the broth microdilution assays 
according to the clinical and laboratory standards institute (CLSI) guidelines (Wayne, 2007). 
Briefly, broth microdilution assays were performed in round-bottom 96-well microplates in 
which drugs were diluted in 7H9 medium using two fold serial dilutions. M. tuberculosis 
strains were grown to OD600 ~ 0.2 in 7H9 medium and used as a starting inoculum following 
five hundred-fold dilution in 7H9 medium. An equal volume of the diluted inoculum strain 
was added to each well of the plate (final volume of 100 μl per well). To minimize 
evaporation of the growth medium during the assay, 200 µL of sterile water was added to 
each outer well of each plate. The plates were incubated for 3 and 8 days for M. smegmatis 
and M. tuberculosis respectively. After the addition of resazurin, the plates were further 
incubated for 1 day in the case of M. smegmatis and 2 to 3 additional days for M. tuberculosis 
(Ramon-Garcia et al., 2011). A change from blue to pink indicated growth of bacteria, and 
the MIC90 was deﬁned as the lowest concentration of drug that prevented this color change. 
For gfp-based-measurement, MIC determinations were performed in black,
 
clear-bottom, 96-
well microplates and fluorescence measured with a Fluostar Optima microplate reader (BMG 
Labtech) using excitation and emission wavelengths of 485 and 508 nm. 
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6.4. Drug interactions (synergy, no interaction, antagonism). 
6.4.1. Checkerboard assay 
2D Checkerboard 
Two-dimensional drug interactions were determined by checkerboard titration in a 96-well 
plate (Figure 6-1).  The two-drug microdilution was carried out with slight modification as 
described by Chen et al (Chen et al., 2006). Briefly, the first serially diluted drug was 
dispensed (2 µl) along the x-axis (columns 3 to 11) at a concentration 100 times higher than 
the final concentration in the well and the second serially diluted (2 µl)) drug in the y-axis 
(row B to H) at a concentration 50 times higher than the final concentration in the 96-well 
microtitre plate. The first column (column 1) and last column (column 12) contained drug-
free control and a control drug concentration giving maximum inhibition respectively. The 
second column from B2-H2, and first row from A3-A11 contained individual drugs. Synergy 
was described by the fractional inhibitory concentration (FIC) index expressed as FICI = 
FICA + FICB = CA
comb
/MICA
alone  
+ CB
comb
/MICB
alone
 where MICA
alone
 and MICB
alone
 are MICs 
of drugs A and B when acting alone and CA
comb 
and CB
comb
 are the concentrations of drugs A 
and B at the iso-effective combinations respectively.  FICI ≤ 0.5 represented synergy; FICI > 
4 antagonism and in between represents no interaction (Odds, 2003).  
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A3  - A11 Drug  
A  alone
B2  - H2 Drug  B  
alone
A12 – H12  Control  wells. Drug  
treated; maximum bacterial inhibition
Drug A
A1 – H1  Control wells. No drug 
; maximum bacterial growth
Drug B
 
Figure 6-1 Schematic representation of a 2D plate layout 
3D Checkerboard 
In the three-drug combinations (Figure 6-2), microdilutions were principally based on the 
standard two-dimensional checkerboard assay. The third drug (2 µl) were then added at a 
concentration 50 times higher than the final concentration in the well as an overlay at sub- 
inhibitory concentrations ranging from 1/32 to ½ of the MIC. Well A2 on all plates contained 
the third drug only. After inoculation with a log-phase culture of M tuberculosis (50µl) to 
each well, the plates were placed in zip-lock bags and incubated for about 2 weeks at 37°C 
before the results were read in the BD plate reader (excitation at 485nm and emission at 
520nm). The mean for the maximum inhibition wells (column 12) was used as a background 
substraction for all other wells. Percent inhibition was defined as 1-(test well fluorescence 
units/mean fluorescence units of max. inhibition wells) x 100 on day 14 of incubation. The 
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lowest drug concentration effecting inhibition of 90% was considered the MIC. Resazurin 
dye was used to visualize the 96-well microtitre plates inoculated with H37Rv (Ma). 
 
 
Figure 6-2 Representation of a 3-drug (3D) combination layout in a 96-well plate 
6.4.2. Time-kinetics assay 
To validate the synergy detected by CB, time-kill analysis was performed. Drug 
combinations and the respective individual drugs were used at their optimal synergistic 
concentration. Briefly, M. tuberculosis strain was grown in 7H9 broth containing 0.05% 
tween-80 with an inoculum of approximately 5 X 10
6
 CFU/ml. Tissue flasks were prepared 
containing each antibiotic alone and their combinations including a control tube without 
antibiotics. Each tissue flask (final volume 10 ml) was inoculated with 100 μl of a 3-day old 
broth culture to give an initial inoculum of approximately 5 x 10
5
 CFU/ml. The flasks were 
incubated at 37 °C. 100 μl aliquots withdrawn at different time points over a period of 14 
days. Ten-fold dilutions of the aliquots were be prepared on 7H9/OA C media and 100 μl 
   120 
 
 
each dilution plated onto 7H10 agar plates containing 10% OADC supplement. Colony 
forming units were then determined after a further 21 days of incubation. 
 
6.5. Ex-vivo interaction study 
6.5.1. Macrophage Growth and Infection  
A 1 ml freezer stock of THP-1 macrophages were thawed by rubbing between gloved hands 
as quickly as possible. To wash out excess DMSO and serum from the cells, the thawed 
freezer stock was added into 9 ml RPMI-1640 of pre-warmed media, supplemented with 10% 
foetal bovine serum (FBS). This was followed by gentle centrifugation, 100 x g for 5 
minutes. The old media was discarded and the pellet resuspended in 10 ml of fresh media. 
Cells were then grown in a 37°C CO2 incubator to a density of between 8 x10
5
/ml and 1.0 x 
10
6
/ml (achieved within 3-4 days) on 50 ml tissue flasks. Afterwards, the cells were washed 
by centrifuging at x 1400g  and resuspending in fresh media. An automated cell counter was 
used test the macrophage viability. The media was changed every 3 days. THP-1 cells were 
passaged only 5 times. No antibiotic was used during the macrophage growth. 
 THP-1 cells were then differentiated with 100 nM phorbol 12-myristate 13-acetate 
(PMA) for 24 h. Thereafter, ~5x10
5
 THP-1 macrophages were infected at a multiplicity of 
infection of 1: 10 bacteria for 3 h at 37°C. Cells were then washed with the media. To release 
the bacteria, macrophages were lysed once with 1x PBS and then with diH2O, with the latter 
being removed immediately. Then, 100 µl of diH20 was added and the cells were incubated at 
24°C for 15 minutes. Finally, 100 µl volume containing lysed cells were pipetted into 900 µl 
of 7H9 medium with 0.05% Tween-80 and serially diluted. The serial dilutions were 
inoculated into the 7H10 agar plates, incubated for 14-21 weeks for CFU enumeration.  
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6.5.2. Synergistic drug interactions against M. tuberculosis-macrophage culture  
 Infected macrophage lysates were treated with the selected anti-TB drugs and/or translational 
inhibitors as single agents or in combination.  As a control, free drug macrophages were 
included. The MICs for the selected drugs were determined by the broth microdilution assays 
according to the clinical and laboratory standards institute (CLSI) guidelines (section 6.3).  
THP-1 cells in the presence of drugs were incubated at 37°C for the required duration of the 
experiment. Afterwards, 20 µl of 0.01% resazurin was added per well and the plate incubated 
for another 24 h. Fluorescence was measured at the excitation and emission wavelengths of 
544 nm and 590 nm respectively for viability determination. 
 
6.6. Bactericidal versus bacteriostatic analysis 
6.6.1. MBC: MIC Ratio 
In this assay, an established technique was used to differentiate the bacteriostatic or 
bactericidal effect of a single drug or drug combination (Figure 6-3). Briefly, the MIC90 of 
the drugs against M. tuberculosis H37Rv::gfp or wild-type strain were first determined in 
7H9 broth using the standard microdilution method on a 96-well plate. Briefly, 2-µl of the 
test drugs were added to the 7H9 medium to make a total of 100µl. This was followed by 2-
fold dilutions on a 96-well plate. 50-µl of mid-log phase culture (OD600 0.6) adjusted to 
approximately 10
5
 CFU/ml were added to the wells. The plates are then packed in zip-lock 
bags and incubated at 37°C for 7 days.  
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Figure 6-3 Bactericidal vs bacteriostatic: Representation of (A) MIC  (B) MBC plates with 
resazurin dye. The standard MIC plate was set-up and incubated for 7 days.  Before 
resazurin was added, 5 µl from every well was transferred to 200 µl of a drug-free medium, 
MBC plate and processed in the same way as the MICplate. Resazurin was added  to the 
MBC plate, incubated for a further 24 – 48 h and the lowest concentrations of the drugs that 
resisted colour change from blue to pink in both plates compare. The respective 
concentrations were used to analyze the MBC/MIC ratios.  MBC/MIC ≤ 2 was considered 
bactericidal 
 
 
Thereafter, the MIC90 was established by measuring fluorescence using the BD microplate 
reader with excitation and emission wavelengths of 485nm and 520nm, respectively. 5- µl 
from every well was later transferred to 100- µl of a drug-free medium in another 96-well 
plate, MBC plate, and incubated at 37°C for a further 7 days.  Fluorescence  was measured on 
day 7. The concentration at which there was 90% or greater inhibition of RFU compared to 
those of untreated cells was defined as the bactericidal concentration. A compound or drug 
combination was considered bactericidal if the ratio between the minimal bactericidal 
concentration MBC99 and the MIC90 was equal to or smaller than 2, that is MBC/MIC ≤ 2. 
Alternatively, when the wild-type strain was utilized, the transfer of 5- µl was effected before 
A
. 
C 
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adding 10- µl per well of resazurin blue, this was then incubated for 24 h. A change from 
blue to pink indicated growth of bacteria, and the MIC was deﬁned as the lowest 
concentration of drug that prevented this colour change. INH, a bactericidal drug was used as 
a positive control. 
 
6.6.2. “Spot-assay” experiment 
A modified assay by Kaur et al. was adopted for this study (Kaur et al., 2015). The spot-assay 
began with a 96-well culture plate, MIC/assay plate, (Figure 6-4).  In brief, 50µl of 
7H9/OADC media was first dispensed across all the wells. Rows 1 and 12 were used as 
media and culture controls respectively. Rows B to G contained the compounds under 
investigation and reference drug controls, FSA and DCS serially diluted from column 1 to 12. 
M. smegmatis pMSP12 gfp strain cells were added to each well of the 96-well plate at 
approximately 7 x 10
4
 CFU/ml. Incubation was performed at 37°C for 3-4 days. After the 
incubation the MIC90 data were recorded using a BD plate reader and the fluorescence 
intensity measured in the bottom-reading mode with excitation at 485nm and emission at 
520nm.   
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Figure 6-4 A plate map for the MIC in a 96-well plate.  Six test drugs (C1-C6) are 
subjected to MIC test as a 10-concentration dose response. The 1
st
 and 8
th
 rows = reference 
drug controls (static and cidal drug). M. smegmatis culture addition was performed with the 
multi-channel pipette and incubation undertaken at 37°C for 3-4 days.  Post – incubation, the 
MIC data were recorded on BD plate reader. 
 
The spot-assay was performed by accurately dispensing 10-µl culture volumes from the 96-
well plate onto 24-well agar plates at 4X, 2X, X and 0.5X MICs (Figure 6-5) , swirled using 
glass beads and incubated at 37°C for 3 days. Visualization assessment was performed once 
growth/colonies appeared on the culture control wells. We hypothesized that under colony 
visualization on the 24-well solid plates, wells consisting of  cidal drugs at 1X MIC and 
above would exhibit  clean solid plates or far less colonies as compared to those wells 
containing bacteriostatic drugs which do not kill the bacteria but merely stops their 
replication at the MIC drug concentration.  
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Figure 6-5 Twenty-four well, 7H10 agar plate. 10µl of culture dispensed in each well 
containing 4X, 2X, 1X and ½ x MIC of test drugs (A, B, C). FSA and DCS used as reference 
static and cidal drugs respectively. 
 
6.7. Isolation of mutants of M. tuberculosis 
To isolate  spontaneous mutants, cultures of wild-type  M. tuberculosis were grown at 37°C 
to OD600 = 0.6, pelleted by centrifugation, and resuspended in Middlebrook 7H9 broth 
supplemented with glycerol, OADC, and 0.05% Tween 80. Aliquots containing 10
7
, 10
8
 and 
10
9
 cells were then plated on Middlebrook 7H10 agar media supplemented with glycerol and 
OADC in the presence of drug at 5 x and 10 x the MIC90 value determined in liquid culture. 
Colonies arising after 1 weeks’ incubation were then picked and sub cultured in Middlebrook 
7H9 containing drug at 1 x MIC90. The bacterial strain was then retested for susceptibility 
with the respective drugs. 
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6.8. Assessment of mycobacterial physiological state and antibiotic treatment  
6.8.1.  Membrane integrity and cell viability assay 
The determination of mycobacterial’s physiological states in exponential and stationary 
phases was perfomed with M. smegmatis mc
2
155 using PI and CA-AM. 
PI staining:  A method by Gonzalez et al., was used with modifications (Gonzalez-y-
Merchand, Jorge A 2012). Bacterial suspensions at different phases, OD600 = 0.5, 2.0 and 3.5 
were ad usted to  106 bacteria per ml and mixed with 1 μM of 1 mg/ml PI fluorescent stain 
(Sigma, USA). Bacterial cells containing PI stain were incubated for 30 min at 24°C. 
Analysis was performed with a fluorescence-activated cell sorting (FACS) Scan Calibur flow 
140 cytometer (BD, Becton Dickinson, USA). PI stain is a fluorescent dye that penetrates 
through the compromised membrane of dead or injured cells. Forward and side scatter 
parameters (both in a logarithmic settings) were measured. Fluorescence of 20000 events 
were analysed with FL3-FSC dot plots.  
CA-AM staining: M. smegmatis staining was performed according to Kramer  et al., (Kramer, 
Wiechert & Kohlheyer, 2016). A 1 mM solution was prepared by dissolving 50µg sample in 
50 µl DMSO. Approximately 10
6
 cells were stained with  1 μM  CA-AM, incubated for 30 
min at 37°C before FCM analysis. Fluorescence of 20000 events were analysed with FL1-
FSC dot plots. 
 
6.8.2. Cell sorting 
M. smegmatis sub-populations analysed by FCM had their sort gates defined on an FL1 vs 
FSC dot plot of CA-AM stained cells. The sorter was set on purity mode, and sorted cells 
collected in two 5-ml tubes. Sorting was stopped after the acquisition of between 100,000 – 
200, 000 cells in each tube. Filter-sterilized PBS was used as the sheath fluid. The sorted cells 
   127 
 
 
were centrifuged at 4000 x g for 5 min, the supernatant removed. The remaining volume with 
sorted cells used for microscopy evaluation.  
6.8.3. Fluorescence microscopy 
Bacterial cell suspensions in 1 x PBS, after cell-sorting were spread on  glass slides and cover 
slips mounted. The slides were placed on a 42°C heating block for 3 min to allow the 
adhesion of M. smegmatis onto the slides before examination under a fluorescence 
microscope (Zeiss AX10 microscope, Carl Zeiss MicroImaging GmbH, Jena, Germany). A 
fluorescence immersion oil was used for the observation at high objective (x100). 
6.8.4. Sample preparation and FCM data acquisistion 
Antimycobacterial agents were prepared with 7H9 broth in 12-ml falcon tubes.Eachdilution 
was then inoculated with   106 cells. Untreated bacterial suspensions were also included as 
controls. The tubes were incubated at 37°C for 72 h and data acquisition on FCM performed 
at 0, 24, 48 and 72 h time points. For FCM analysis, 1µl of 1 mM CA-AM solution was 
added to the suspensions to yield a final concentration of 1 µM. The samples were incubated 
at 37°C for 30min before being analysed with a 488nm argon laser (FACScanflow cytometer; 
Becton Dickinson Immunocytometry Systems) using FACProSort software. 
 
6.8.5. Flow cytometric statistical analysis. 
Samples were analyzed by examining histogram profiles of CA-AM fluorescence with 
Flowjo v.10 software. The percentage of CA-AM -ve and +ve cells upon antibiotic treatment 
was evaluated. 
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APPENDICES 
Appendix 1: Culture media  
All media were made to a final volume of 1L with distilled water. Media were sterilized by  
autoclaving at 121°C for 15 min.  
7H10/OADC Agar 
 19 g Middlebrook 7H10 agar powder (DifcoTM, USA), 5 ml glycerol (Merck, Germany)  
100 ml Middlebrook OADC Enrichment (BD Microbiology Systems, USA) added after  
autoclaving.  
7H9/OADC Liquid 
  4.7 g Middlebrook 7H9 broth powder (DifcoTM, USA), 2 ml glycerol (Merck, Germany) 
100 ml OADC Middlebrook OADC Enrichment (BD Microbiology Systems, USA) added 
after autoclaving. 
Appendix 2: In vitro MIC90 of FSA and its selected derivatives against M. tuberculosis 
H37Rv (wild-type) strain and FSA-R mutant 
Compound  
14 day 7H9/OADC MIC90 
(µM) with H37Rv  
14 day 7H9/OADC MIC90 
(µM) with FSA-R  
FSA  2.4  20  
GKFA17  33  80  
GKFA37  0.5  80  
GKFA51  5.2  160  
GKFA 61  14  >160  
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Appendix 3:  Spot Assay:  MIC90  96-well microtitre plate experiment for the MIC90  
analysis against M. smegmatis::gfp 
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